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1  Introduction 
1.1 The diabetic epidemic – a challenge for the 21st century 
30 million, 135 million, 217 million - the worldwide prevalence of diabetes in 
1985, 1995 and 2005 reached an alarming epidemic state and is estimated to shoot 
up to 366 million people in 2030 (1). This disease is not restricted to modern 
Western Societies - it is a worldwide growing public health burden with 80% of 
diabetics who live in low and middle income countries (2). Most people suffering 
from diabetes are from India (51 million), China (43 million) and the USA (27 
million), (3). Strikingly, the relative prevalence is highest for countries in Middle 
East and Caribbean regions (10% each, Figure 1).  
 
Most of these patients are affected by the non-insulin-dependent form of diabetes 
(type 2 diabetes), which is characterized by an impairment of the body for insulin 
action (insulin resistance) and a depletion of insulin-producing pancreatic β-cells 
(relative insulin deficiency) (4). In general, pancreatic islet β-cells are capable of 
counteracting decreased insulin sensitivity by increased insulin release (5), but 
eventually this reciprocal response is disordered at the progression of type 2 
 
 
Figure 1. Global prevalence (%) of diabetes (20-79 years) in 2010 (3). 
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diabetes mellitus, including elevated concentrations of blood glucose. Chronic 
hyperglycemia leads to dysfunction of various organs, especially the blood vessels 
(atherosclerosis), kidneys (nephropathy), eyes (retinopathy) and nerves 
(neuropathy). About 50% of diabetics die of cardiovascular diseases such as 
stroke. Diabetes is a leading cause of kidney failure, resulting in 20% mortality 
rate provoked by renal failure. Diabetic neuropathy affects about 50% of people 
having diabetes and can be accompanied by e.g. pain, foot ulcers and 
gastrointestinal symptoms. Ten percent develop severe visual impairment such as 
blindness (2). Other comorbidities like depression further dramatically decrease 
the quality of life (6). In summary, diabetes and its complications are considered 
the major cause of death in many countries, constituting 7% of global mortality. It 
entails a huge impact on the public health systems. Twelve percent of the public 
healthcare expenditure in 2010 were attributed to type 2 diabetes (1, 3). Therefore, 
the high prevalence and rapid increase in diabetes is a global challenge for the 21st 
century.  
  
1.2 Going hand in hand: Insulin resistance, obesity and inflammation 
1.2.1  Evolutionary considerations 
As proposed by Neels thrifty genotype theory in 1962 (7), genes rendering 
susceptible to obesity may have conferred an evolutionary advantage in times of 
famine through efficient energy storage. In the last thousands of years the genetic 
adaptation could not keep up with the environmental and dietary alterations 
accompanied by substantial progress in agriculture, industrialisation and 
automation. As a result, the inherited ‘hunter-gather’ genotype can be denoted as 
ill-suited under high-caloric and sedentary conditions. 
During the past decades, it became obvious that obesity and diabetes are also 
causatively linked to inflammation. However, metabolic overload-derived 
inflammation is distinctive from classical inflammation. The former is modest, 
chronic and unresolved over time (8). From an evolutionary perspective, mankind 
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was not only confronted with famines, but also with infectious diseases, 
additionally leading to selection of strong immune responses. Under certain 
conditions, the coordinated regulation of immunity and metabolism may be 
beneficial from a physiological perspective. Immune responses require 
redistribution of energy. A host strategy could be to minimize anabolic processes 
(e.g. by insulin resistance) to withhold structural components of the pathologic 
invader (9). But as optimised metabolic efficiency, immune responses that are too 
sensitive could be disadvantageous in times of caloric excess. The evolution of fat 
tissue, liver and immune cells emphasizes the association between inflammation 
and metabolic diseases. Whereas these tissues are separated in mammals, they all 
are organized in one functional unit, the fat body, in ancestral organisms such as 
Drosophila (9).  
 
1.2.2  Insulin resistance 
Insulin is a very potent anabolic hormone that regulates various metabolic and 
developmental processes (Figure 2). Insulin resistance is a pathophysiological 
state characterised by impaired insulin signalling and precedes the manifestation 
of type 2 diabetes. Without action of insulin blood glucose is not properly 
absorbed and hepatic glucose production is not inhibited. Hyperglycemia is of 
central pathophysiological importance. Different biochemical mechanisms have 
been postulated for hyperglycemia-induced tissue damage, including glycation of 
tissue proteins, elevated polyol pathway and hexosamine pathway flux as well as 
activation of protein kinase C (PKC) (10). Consistently, all these mechanisms lead 





















The risk of developing type 2 diabetes is correlated to obesity, physical 
sedentariness, nutrition, and genetic predisposition amongst others (3, 4, 11, 12) 
(13). The concurrent epidemic of obesity indicates the causal connection to the 
formation of diabetes, as about 90 % of people with type 2 diabetes are obese or 
overweight (14). This correlation was already described with the term ‘diabesity’ 
in 1980 by Ethan A. H. Sims (15). 
 
1.2.3  Obesity 
Obesity is characterized by excessive fat accumulation in adipose tissue. By 
definition, overweight and obesity are existent with a body mass index (BMI) 
greater than 25 or 30 kg/m², respectively (16). The number of overweight and 





Figure 2. Regulation of metabolism by insulin. Insulin regulates the homeostasis of 
carbohydrates, proteins and fats. Insulin, released from pancreas after postprandial blood 
glucose elevation, stimulates the uptake of glucose, amino acids and free fatty acids (FFA) 
in different cell types. It promotes the storage of substrates in liver, muscle and fat by 
activating glycogenesis, lipogenesis, glycolysis and protein synthesis, and inhibition of 
glycogenolysis, proteinolysis and lipolysis. Red arrows indicate metabolic processes, blue 
arrows indicate regulation by insulin. Adopted from ref. (11). 
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disorder is not restricted to Western societies but increasingly affects people in 
newly industrializing countries (14). Although most of diabetic people are obese 
or overweight, the reverse is not true. The rationale is the distribution of body fat. 
Visceral (abdominal) obesity, but not peripheral obesity, is associated with insulin 
resistance and cardiovascular diseases (17, 18). This is also reflected by the 
recommendation of the US National Institutes of Health (19) to measure waist 
circumference rather than BMI. Intra-abdominal adipocytes are closer to essential 
organs such as liver and pancreas, and are primarily involved in secretion of 
proteins and peptides responsible for metabolism (20). Furthermore, compared to 
peripheral fat tissue, visceral fat is less sensitive to the anti-lipolytic effect of 
insulin (21) accompanied by higher concentration of detrimental free fatty acids.  
 
1.2.4  The connection between diabetes, obesity and inflammation 
Several mechanisms for the link between insulin resistance and obesity are 
obvious. The prevalent lipotoxicity or lipid overload hypothesis assumes an 
accumulation of fat in muscle, liver and pancreas cells, when adipose tissue 
cannot store excessive fat properly. Then, elevated intracellular lipids result in an 
accumulation of metabolites such as fatty acyl-coenzyme A, diacylglycerol 
(DAG) and ceramides. These metabolites lead to inhibition of insulin-signalling 
via activation of protein kinase C (PKC) (22, 23) and serine/threonine kinase 
cascades including inhibitor kappa B kinase (IKK) and JUN N-terminal kinase 


























Besides, Randle et al. proposed a competition of fatty acids with glucose for 
oxidation resulting in the inhibition of activity of the pyruvate dehydrogenase, 
phosphofructokinase and hexokinase II and thus to diminished glucose import into 
the cell (24). Additionally, recent studies revealed that the endoplasmatic 
reticulum (ER), the organelle responsible for protein folding and maturation, 
mainly contributes to the obesity-related progression of insulin resistance. 
Nutrient excess leads to an accumulation of newly synthesized, unfolded proteins 
in the ER, which thereon activates the unfolded protein response (UPR) (25). 
  
   
 
Figure 3. Lipid overload (left) and macrophage attraction hypothesis (right) linking 
obesity with low-grade inflammation and insulin resistance. (Left) Enlarged adipocytes 
secrete a huge amount of fatty acids that accumulate in form of diacylglycerols (DAGS) in 
the muscle tissue. DAGS activate a panel of stress-sensitive protein kinases C (nPKCs) 
leading to inhibition of insulin signalling through serine phosphorylation of insulin 
receptor substrate 1 (IRS-1). (Right) Enlarged adipocytes accumulate macrophages, 
resulting in secretion of pro-inflammatory cytokines. In the muscle cell these molecules 
activate the JUN N-terminal kinase (JNK) that inhibits insulin signalling through serine 
phosphorylation of insulin receptor substrate 1 (IRS-1). Adopted from ref. (188). 
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Three branches mediate the UPR, including PERK (PKR-like eukaryotic initiation 
factor 2α kinase), IRE1 (inositol requiring enzyme 1), and ATF6 (activating 
transcription factor-6). Finally, the UPR triggers an activation of JNK, IKK, 
NF-κB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) and an 
increase in reactive oxygen species leading to inflammatory conditions (26). It 
further was postulated that nutrient overload and pathogens activate the eIF2α 
kinase PKR (double-stranded RNA-activated protein kinase), which thereon 
triggers the assembly of the metabolic inflammasome (metaflammasome). Thus, 
insulin signalling is impaired (27). 
The adipose tissue has a pivotal role in storage of detrimental body fat. Inhibition 
of white adipose tissue development in transgenic mice leads to an accumulation 
of fat in internal organs such as the liver, and consequently to lipoatrophic 
diabetes (28). Reversely, transplantation of adipose tissue restores the metabolic 
phenotype (29). Concordantly, expansion of the adipose tissue by overexpression 
of adiponectin increases insulin sensitivity although the mice become morbidly 
obese (30). These and further studies underscore the importance of the adipose 
tissue as a compartment of body fat storage.  
Besides, adipose tissue does not only store triglycerides, but functions as 
endocrine organ that secretes many proteins and peptides (adipokines) involved in 
metabolism and immunity (31, 32). This includes adiponectin, leptin, resistin, 
tumor necrosis factor α (TNFα) and monocyte chemotactic protein-1 (MCP-1) 
(33). Adipokines not only modulate glucose and lipid metabolism directly, but 
additionally have important immune functions (34). Impressively, more than 100 
molecules involved in immunity are expressed in adipocytes (34). Furthermore, 
adipocytes themselves are responsive to immunomodulating molecules, since they 
express various receptors such as the toll-like receptor (TLR) family, interleukin 6 
(IL-6) receptor and TNFα receptor (34).  
The association between insulin resistance and inflammation was already 
observed in 1978 in studies of sepsis (35), and was meanwhile verified in many 
infectious or inflammatory disorders (36-38). On the other side, in obese 
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individuals the inflammatory cytokine TNFα is overexpressed in adipose tissue 
(39) and is one of the major risk factors in obesity-related insulin resistance (40). 
The reverse could be shown by inducing insulin resistance in fat cells by TNFα 
treatment (39). Further, obese mice lacking TNFα or its receptors are protected 
from insulin resistance (39). TNFα could be shown to inhibit the insulin pathway 
by changing important phosphorylation states of insulin receptor, IRS and protein 
phosphatase-1 (41, 42).  
Additional immunomodulating adipokines were shown to impair insulin 
sensitivity. The chemokine MCP-1 is overexpressed in obese mice and induces 
insulin resistance in adipocytes (43). In several studies markers of the acute-phase 
response, IL-6 (44) and C-reactive protein (CRP) (45), were increased in diabetic 
patients. Reduction of IKKβ expression leads to improved insulin sensitivity in 
vivo (46). Concordantly, it was shown that IKKβ-inhibiting salicylates, which are 
used to treat inflammatory diseases, also reduce blood glucose in the clinical 
usage (47). JNK1, another key mediator of inflammatory responses, is linked to 
insulin sensitivity. JNK1 is overexpressed in obese mice and knocking it out 
protects from insulin resistance and adiposity (48). The pro-inflammatory 
cytokine interleukin 1 (IL-1) has been found in pancreatic β-cells from diabetic 
patients. In a clinical trial drugs that block IL-1 were able to improve glycemia 
and β-cell secretory function (49).  
Mice lacking the gene for the pathogen-sensing toll-like receptor 4 (TLR4), which 
in general is expressed in adipose tissue, are protected against obesity provoked 
by a saturated fatty acid rich diet (50). This observation confirms a ‘mistaken 
identity theory’ (8) - the system considers abundant nutrients as pathological 
molecules and immune-response pathways become activated (e.g. through TLR4). 
Consequently, key genes in inflammation-signalling pathways are causatively 
linked to insulin responsiveness and adiposity.  
Immunohistochemical and expression analysis of adipose tissue from obese and 
insulin resistant mice revealed, that obesity is accompanied by macrophage 
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infiltration into the fat tissue. This recruitment leads to activation of inflammatory 
pathways (51, 52).  
Secretion of pro-inflammatory molecules by adipocytes and immune cells 
increases macrophage attraction and activation, synergistically stimulating 
inflammatory activity of the other (53). This crosstalk is especially based on free 
fatty acids, MCP-1, TNFα, IL1-β and IL-6 and leads to a vicious cycle of 
inflammation resulting in insulin resistance (Figure 3, right, pg. 12) (54). 
Hence, type 2 diabetes and obesity are considered as chronic low-grade 
inflammation. This ‘metaflammation’ is present in metabolic active tissues like 
adipose tissue, liver, muscle, pancreas and also brain (8). Noteworthy, it recently 
was shown that adiposity-induced insulin resistance in mice could be improved by 
immunotherapy (55). However, from a therapeutic perspective, the preferential 
target of treatment should focus on the nutritional overload, since inhibition of 
inflammation alone may not restrain the high caloric diet-induced risk of tissue 
damage.  
 
1.2.5  The role of pathogens 
Metabolic inflammation that underlies diabetes and obesity may also involve a 
role of pathogens. Indeed, it could be shown that adipocytes can be a direct target 
for parasites and viruses that contribute to metabolic abnormalities (56, 57). 
Especially the intestinal microbiota, composed of hundreds of billions of 
prokaryotics and eukaryotics belonging to 40,000 different species (58), has an 
important role in maintaining physiologic functions of the host. The gut 
microbiota extends the metabolic abilities of the host by producing essential 
vitamins including vitamin K, vitamin B12 and folic acid, and further by 
modulating intestinal bile acid metabolism (59). Additionally, the gut microbiota 
can improve the digestion and absorption of ingested nutrients and modulate the 
host energy metabolism by food-derived signalling molecules like short-chain 
fatty acids and glucagon-like peptides (60). Besides, high-fat feeding leads to 
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increased migration of bacterial membrane-derived lipopolysaccharides (LPS) 
into the blood (61, 62), which contributes to systemic insulin resistance (63, 64). 
Consistently, germ-free mice are protected against high-fat diet-induced obesity 
(DIO) and glucose intolerance (65, 66). Further evidence for a causative role of 
the microbiota comes from a recent study that has shown the transferability of the 
diabetic phenotype by intestinal microbiota inoculation (67). The link between 
human health and gut microbiota will gain deeper insight by progress in 
metagenomic research, e.g. by he Human Microbiome Project (HMB) (68). 
 
1.3  Nuclear receptors 
The nuclear receptor (NR) superfamily comprises a group of ligand-induced 
transcription factors that regulate a huge amount of physiological processes, 
including development, reproduction, and metabolism. Their physiological 
significance is exemplified by the variety of ligands in current clinical and 
developmental treatments of metabolic disorders such as type 2 diabetes, 
atherosclerosis, dyslipidemia, and cancer. The human genome encodes 48 
different nuclear receptors (49 in mouse). The glucocorticoid receptor was firstly 
isolated and cloned in 1985 (69). In the subsequent years, many other NRs were 
identified by screening of newly sequenced genomes.  
From an evolutionary point of view, nuclear receptors are ancient and arose 
together with the need of multicellular organisms to regulate metabolism and 
development. The NR ancestor probably acted as a ligand-independent monomer. 
With acquiring the ability for homo- and heterodimerization and for being 
regulated by ligands, the increasing functional complexity of gene regulation 
potentially expedited the evolution of higher organisms (70). The evolutionary 
oldest NRs (e.g. the retinoid X receptor RXR) were found in Coelenterata and a 
major diversification occurred in insects. Steroid receptors have evolved in the 
chordate lineage (71). Taken together, the complexity of nuclear receptors has 
been increased in parallel to the complexity of the transcriptional machinery rising 
during evolution. 





Figure 4. Canonical structure of nuclear receptors. The architecture comprises the N-
terminal activation function 1 (AF1) domain, the DNA binding domain (DBD), the flexible 
hinge region, the ligand binding domain (LBD) and the C-terminal activation function 2 
(AF2) domain. 
All nuclear receptors share the common structural architecture depicted in 
Figure 4. The highly variable N-terminal region comprises the ligand-
independent transactivation domain (AF1), which is constitutively active and can 
be regulated by covalent modification (72). The central DNA-binding domain 
(DBD) consists of two highly conserved zinc-finger motifs that target the nuclear 
receptor to its specific DNA response elements. In general, the response element 
is composed of two copies of a (A/G)GGTCA hexanucleotide or a modification 
thereof. The hexanucleotides are arranged in an inverted, direct, or everted repeat, 
and they are separated by a NR-specific number of nucleotides. The amino acids 
between the last two cysteins of the first zinc finger form the P-loop that is mainly 
responsible for the binding to the NR-specific DNA response element (71). The 
DBD of the NR is connected to the C-terminal region via a flexible, non-
conserved hinge region, which optionally contains a nuclear localisation signal 
(71). The C-terminal ligand-binding domain (LBD) is less conserved among the 
NRs but functionally unique – the LBD enables ligand recognition, dimerisation 
with other NRs, and interaction with cofactors (72). In general, the LBD 
comprehends 11-12 α-helices arranged with 2-4 β-sheets in an antiparallel, three-
layered sandwich. Small molecule ligands bind to a hydrophobic cavity in the 
core of the LBD. The size of the binding pocket ranges from 350 to more than 
1300 Ǻ3 and determines the promiscuity and affinity of potential ligands (73). The 
C-terminal end of the LBD often contains the conserved activation function 2 
(AF2) domain, allowing ligand-dependent interaction with transcriptional 
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Figure 5. Mechanism of transcriptional activation through heterodimeric nuclear receptors. 
(Left) In absence of ligand these nuclear receptors repress target gene expression by 
recruitment of transcriptional corepressor complexes via the activation function 2 (AF2) 
domain. (Right) Binding of ligands triggers conformational changes in the AF2 domain 
leading to replacement of corepressors by coactivators, which facilitate the recruitment of 
the transcription machinery and target gene expression. Adopted from ref. (189) 
The ligand binding is accompanied by a conformational change within the LBD, 
especially in the last α-helix (often helix 12) (74). This spatial rearrangement 
modulates the interaction with various coactivators and corepressors (72). 
According to the classical concept, in the absence of a ligand the NR is associated 
with corepressors (e.g. nuclear receptor corepressor (N-CoR) and HDAC3 histone 
deacetylases), leading to transcriptional inhibition. In contrast, binding of agonists 
results in the release of corepressors and recruitment of coactivators (e.g. 
members of the steroid receptor coactivator (SRC) and CBP/p300 histone 
acetyltransferases) and thus triggers transcriptional activation (75) (Figure 5). 
Hence, the structural property of the bound ligand determines the induced 
conformational change and thus the specific release or recruitment of different 
transcriptional cofactors. Some NRs (e.g. the estrogen-related receptor ERR) 
contain an AF2 domain fixed in an active conformation, so that the nuclear 
receptor becomes constitutively active. If so, the activity of the NR is modulated 
by cofactor availability, NR expression itself or covalent modification like 
phosphorylation or acetylation (72). 
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Several classification strategies have been reported. Based on their dimerisation 
and DNA binding behaviour the nuclear receptor superfamily is divided into four 
groups. The first subfamily comprises steroid hormone receptors that are localised 
in the cytoplasm and translocate to the nucleus upon ligand binding. The NRs then 
form homodimers and bind palindromic response elements on the DNA. The 
second subfamily consists of NRs, which are retained in the nucleus 
independently of ligand binding and form heterodimers with RXR to recognize 
directly repeated response elements. The second group comprises the peroxisome 
proliferator-activated receptor (PPAR) amongst others. The third subfamily of 
NRs are homodimeric, direct repeat-binding, orphan receptors, with their ligands 
still unknown. The members of fourth group are monomeric orphan receptors (71, 
76). Accounting for evolutionary relationships using sequence alignment 
procedures the nuclear receptor superfamily can also be divided into 7 groups (0 
to 6) (77). This phylogeny-based nomenclature is approved by the Nuclear 
Receptor Nomenclature Committee and is integrated in the official gene symbol.  
 
1.3.1  The peroxisome proliferator-activated receptor (PPAR) 
The peroxisome proliferator-activated receptor (PPAR) was first cloned by 
Issemann and Green in 1990 (78). The term PPAR is based on early observations 
of peroxisome proliferation after treatment of rodents with PPAR ligands (79) 
(80). Nevertheless, PPARs do not induce peroxisome proliferation in primates or 
humans (81). However, they are key regulators of metabolic pathways like energy 
metabolism, adipogenesis and insulin sensitivity (82, 83). According to the 
evolutionary relationship, the PPARs belong to the first group. The PPAR forms 
heterodimers with RXR and binds to the response element composed of the 
consensus sequence AGGTCA with a single nucleotide spacing between two 
repeats (direct repeat 1). The PPAR response element (PPRE) is often present in 
multiple copies in the promoter region but can also be located in the transcribed 
region of target genes (83).  
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A wide variety of natural or synthetic compounds was identified as PPAR ligands. 
Binding of ligands occurs with high promiscuity, and known PPAR ligands are 
strikingly structurally diverse. This is due to the large solvent-accessible cavity in 
the ligand binding pocket, which is over 1000 Ǻ3 in volume (73). PPARs are 
capable of binding to a variety of fatty acids and their metabolites with medium to 
low affinity, indicating that their physiological activation is not restricted to a 
single ligand, but rather involves interactions with numerous fatty acids and their 
metabolites (73). Hence, PPARs act as lipid sensors that induce lipid storage or 
catabolism and thus translate “what you eat” in “what you are” (84). Among the 
synthetic ligands, several glucose- or lipid-lowering drugs are PPAR agonists, 
underscoring the important role of PPARs as therapeutic targets. The PPAR/RXR 
heterodimers are permissive as they can be activated by PPAR agonists as well as 
by RXR ligands alone (85).  
Three PPAR subtypes characterised by distinct tissue distribution, target genes 
and ligands, each encoded in a separate gene, have been identified: PPARα, 
PPARβ/δ and PPARγ. PPARα was the first murine PPAR subtype characterized 
in 1990 (78), many decades after the clinical introduction of the PPARα-
activating fibrates (see below). Two years later, the group of Walter Wahli 
reported the cloning of three different PPAR subtypes in Xenopus laevis, which 
were named PPARα, PPARβ and PPARγ (86). Subsequently, the mammalian 
orthologs of PPARβ and PPARγ were characterized (73). Since the sequence of 
murine PPARβ was less conserved in Xenopus laevis, it originally was named 




PPARα has been shown to play a key role in the regulation of fatty acid 
catabolism, glucose homeostasis and lipoprotein metabolism (78). It is expressed 
in metabolically active tissues such as liver, heart, skeletal muscle and kidney 
(88), and also in immune cells like macrophages (89). Target genes of PPARα are 
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involved in uptake, intracellular transport and β-oxidation of fatty acids (90). This 
include the fatty acid transport protein (FATP), carnitine palmitoyltransferase I 
(CPT1) and acyl-CoA oxidase 1 (ACOX1). Besides, further enzymes for 
lipoprotein metabolism are transcriptionally regulated (83, 91). PPARα-null mice 
show hepatic steatosis when fed a high-fat diet (HFD), and display hypoglycemia, 
hypoketonemia, and hypothermia besides elevated plasma free fatty acid levels 
under fasted conditions (92). It recently was shown that PPARα can be activated 
by endogenous α-linoleic acid (93) and 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine (94) besides other such as unsaturated fatty acids and eicosanoids 
(95). Chemical activation of murine PPARα results in decreased serum 
triglyceride levels, increased high density lipoprotein (HDL) levels (82), 
improved insulin sensitivity and lowered blood glucose and insulin concentrations 
(96). Synthetic fibrates (e.g. bezafibrate, fenofibrate) are potent agonists of 
PPARα and are widely used in the clinical treatment of hypertriglyceridemia for 
about 50 years (97). In addition to cholesterol-lowering statins, fibrates are often 
combined with niacin and omega-3 fatty acids. Some side effects comprise 
gastrointestinal symptoms (98). 
 
1.3.1.2 PPARβ/δ 
PPARβ/δ is ubiquitously expressed in all tissues and involved in the regulation of 
fatty acid oxidation, epidermal development, cell proliferation, cancer and 
inflammation (83, 99). Transgenic mice overexpressing PPARβ/δ in adipose 
tissue are protected from obesity during a HFD, whereas adipose tissue-specific 
deletion leads to obesity (100). Concordantly, pharmaceutical activation of 
PPARβ/δ was shown to ameliorate insulin resistance in different mouse models 
due to increased lipid catabolism (99). Furthermore, its activation in mice 
enhanced running endurance without exercise (101). Specific ligands (e.g. 
GW1516, MBX-8025) are currently in various stages of clinical development 
(102). 
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1.3.1.3 PPARγ 
PPARγ plays a key role in glucose and lipid homeostasis. It is a regulator of 
several developmental processes such as adipogenesis and bone formation, and 
additionally, has anti-inflammatory and cancer-modulating properties (84, 103, 
104). While the PPARγ1 isoform is predominantly expressed in liver, intestine, 
kidney, macrophages and adipocytes, PPARγ2, exhibiting an additional N-
terminal 28 amino acid residue, is exclusively expressed in adipose tissue (104, 
105). 
Various target genes of PPARγ have already been identified. These include the 
fatty acid binding protein (FABP), the acyl-CoA synthetase (ACS), the lipoprotein 
lipase (LPL) (106) and the fatty acid transport protein 1 (FATP1) (107). These 
gene products are required for adipogenesis and uptake of serum fatty acids. The 
phosphoenolpyruvate carboxykinase (PEPCK) (108), the glycerol kinase (GyK) 
(109) and the glycerol transporter aquaporin 7 (110) promote the intracellular 
storage of detrimental lipids (104). Taken together, these pathways lead to the net 
flux of fatty acids from serum and other tissues (e.g. liver, muscle) into 
adipocytes. Thus, the level of free fatty acids in serum is decreased. Furthermore, 
activated PPARγ increases the transcription of the insulin responsive glucose 
transporter GLUT4 in fat and muscle cells, thereby reducing blood glucose levels 
(107). In addition, expression of secreted adipokines like TNFα, leptin and resistin 
is decreased, while expression of adiponectin is up-regulated upon PPARγ 
activation (107). Consequently, PPARγ activation results in decreased insulin 
resistance and has anti-inflammatory and anti-atherogenic properties (Figure 6). 
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Figure 6. Potential mechanism of insulin sensitisation by PPARγ ligands. In adipose 
tissue, activation of PPARγ leads to increased gene expression of PEPCK, FATP1, 11β-
HSD1, GyK and CD36, resulting in an influx of free fatty acids (FFA) from serum and 
other tissues into adipocytes. This decreases the level of detrimental free fatty acids in 
serum. Further, expression of secreted adipokines such as TNFα, leptin, resistin, IL-6 and 
PAI-1 is reduced, while expression of adiponectin stimulating fatty acid oxidation is 
increased. Consequently, PPARγ activation results in improved insulin sensitivity and anti-



















Several mechanisms for the anti-inflammatory effects of PPARγ have been 
observed, including increased expression of anti-inflammatory molecules and 
negative regulation of pro-inflammatory genes (derepression). Further anti-
inflammatory processes are independent of direct DNA-binding of PPARγ 
(transrepression). This comprises binding of PPARγ and susbequent inhibition of 
pro-inflammatory AP1 and NF-κB, and nucleocytoplasmatic redistribution of the 
p65 subunit of NF-κB. Transrepression is further achieved by modulation of 
MAPK14 (mitogen-activated protein kinase 14) activity and competition for 
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limiting pools of coactivators (111). Additionally, it was shown in macrophages 
that activated PPARγ becomes SUMOylated and subsequently binds to 
corepressors, which prevents its degradation by the 19S proteasome. 
Consequently, pro-inflammatory genes are maintained in a repressed state (112). 
Generation of PPARγ-null mice results in embryonic lethality due to placental 
dysplasia and dyslipidemia (113). Transgenic mice lacking PPARγ in fat, muscle 
or liver develop insulin resistance (114-117). Further conditional knockout studies 
confirm the protective role of PPARγ in glucose and lipid homeostasis (83). 
Macrophage-specific PPARγ knockout mice show reduced cholesterol efflux 
leading to atherosclerosis (118). Intriguingly, heterozygous PPARγ knockout mice 
reveal reduced adiposity and are protected from HFD-induced insulin resistance 
(119, 120). Additionally, human genetic studies demonstrated that a specific 
Pro12Ala substitution with lessened PPARγ activity observed in Pima Indians and 
others is correlated to improved insulin sensitivity and reduced risk of type 2 
diabetes (121-123). By contrast, the rare Pro115Gln mutation leads to constitutive 
activation of PPARγ and, noteworthy, to obesity (124). Complete loss of function 
mutations (Phe388Leu, Pro495Leu, Arg425Cys) have been associated with 
lipodystrophy and diabetes (84). 
Endogenous ligands for PPARγ comprise 15-deoxy-prostaglandin J2 (125), 
linoleic acid, linolenic acid, eicosapentaenoic acid, 9- and 13-
hydroxyoctadecadienoic acid (9-HODE, 13-HODE) (126), and 15-
hydroxyeicosatetraenoic acid (15-HETE) (127) beside other fatty acid- and 
arachidonic acid derivatives.  
Thiazolidinediones such as rosiglitazone (Avandia) and pioglitazone (Actos) are 
widely used as anti-diabetic drugs and have been shown to strongly activate 
PPARγ (128, 129). Originally, thiazolidinediones were derived from clofibrate 
due to its glucose lowering effects (130), without any knowledge about the 
molecular target (128). Unfortunately, thiazolidinedione treatment is accompanied 
by several side effects such as weight gain, congestive heart failure, and 
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osteoporosis amongst others (104, 131, 132). Recently, the regulatory agencies 
therefore restricted or even suspended rosiglitazone in the US and in the EU, 
respectively (131).  
The adverse safety profile of these fully activating PPARγ agonists and the 
genetic studies mentioned above demonstrate that partial rather than full 
activation of PPARγ may improve insulin sensitivity while unlinking unwanted 
side effects. These considerations led to the concept of selective PPAR 
modulators (SPPARMs) (133). This model is derived from the approved selective 
estrogen receptor modulators (SERMs) such as tamoxifen (134, 135). According 
to the SPPARM concept, chemically diverse PPARγ ligands bind in distinct 
manners to the LBD of PPARγ. This results in different conformational changes 
of the nuclear receptor, especially at helix 12, and thus, in ligand-specific 
interactions between PPARγ and transcriptional coactivators and corepressors. 
Consequently, different genes in specific tissues are modulated in differential 
manners. Beneficial gene regulation may become uncoupled from adverse effects 
by SPPARMs, providing an optimized insulin-sensitizing compound (74, 104, 
136). Currently, several SPPARγMs are in clinical and preclinical development. 
For instance, telmisartan, nTZDpa and halofenate could be shown to partially 
activate PPARγ without inducing weight gain (137). 
Another promising approach for the development of novel PPARγ ligands is the 
concept of dual PPARα/γ or even pan PPARα/β/δ/γ agonist. As single activation 
of the three isotypes has different clinical outcomes, e.g. on the lipid profile, a 
combination of therapeutic effects is thought to show improved efficacy for the 
treatment of type 2 diabetes and dyslipidemia (138). Among these dual PPARα/γ 
agonists, the glitazars are in the most advanced stage of development. In clinical 
trials muraglitazar (139), aleglitazar (140), tesaglitazar (141) improved insulin 
sensitivity and ameliorated the lipid profile. But the development of many 
glitazars had to be discontinued due to severe side effects such as carcinogenic 
effects, weight gain, edema and cardiovascular events (142).  
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Recent studies suggest that a small molecule targeting all three PPAR subtypes 
may provide improved efficacy and safety profiles. The therapeutically used 
bezafibrate, already introduced in 1977, is rather a pan-PPAR agonist than a 
specific PPARα ligand, as it activates all three PPARs with similar effectiveness 
(143). Indeed, bezafibrate not only reduces triglycerides and increases high-
density lipoprotein-cholesterol, but further reduces insulin and glucose levels 
without long-time safety concerns (143). However, its low potency in activating 
PPARs necessitates the development of more powerful compounds. Candidates in 
early development stages include indeglitazar (144) and sodelglitazar 
(GW677954) (145, 146). In spite of the promising preclinical and clinical data for 
novel PPAR agonists, further studies, especially investigating long-time safety, 
are required.  
The concerns about safety of PPAR agonists raised scepticism on PPAR as 
therapeutic target in the last years. Though, recent findings (147) raise hope for 
the success of novel PPARγ ligands. Obesity is associated with inflammation-
derived PPARγ phosphorylation at serine 273 in adipose tissue. Inhibition of this 
phosphorylation was achieved by PPARγ ligands, and strikingly, ligand-induced 
inhibition of the phosphorylation was independent from the magnitude of receptor 
agonism. The partial PPARγ agonist MRL-24 showing low transcriptional 
activation was as efficient as the full agonist rosiglitazone in inhibition of 
Ser-273-phosphorylation, indicating that agonist and phosphorylation effects are 
independent from each other. This suggests that the tremendous effects of obesity 
and high-fat diet are mediated by Ser-273-phosphorylation of PPARγ and could 
be prevented by ligands with less transcriptional activation. This may reduce the 
risk of potential side effects (147). Whereas the primary aim in the field was to 
develop highly activating PPARγ agonists, ligands with low or even without 
agonism now seem to have promising properties by separating anti-diabetic from 
unwanted side effects (148-150). 
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1.4  Pharmacological treatment of type 2 diabetes 
The aim of pharmacological treatment is to reduce hyperglycemia but to avoid 
disabling hypoglycaemia in parallel to lifestyle and dietary interventions. Whereas 
individuals with type 1 diabetes are strictly dependent on insulin administration 
due to pancreatic defects, for treating type 2 diabetes oral anti-diabetic drugs are 
usually sufficient. Besides several insulin formulations and analogues, the 
following drug classes are currently approved for the treatment of diabetes: 
biguanides, sulfonylureas, meglitinides, thiazolidinediones, α-glucosidase 
inhibitors, GLP-1 analogues, DPP-4 inhibitors and amylin analogues. 
Metformin (dimethylbiguanide) is the worldwide most prescribed anti-diabetic 
drug (151) and it is the agent of first choice for the treatment of type 2 diabetes 
(152). Its mode of action is to activate the AMP-activated protein kinase (AMPK) 
in the liver (153), that regulates cellular glucose and lipid metabolism (154). Thus, 
metformin reduces hepatic production and secretion of glucose and partially 
increases extrahepatic insulin sensitivity (155). 
Sulfonylureas (e.g. glimepiride) have been extensively used for decades. They 
stimulate ATP-dependent potassium channels on the cell membrane of pancreatic 
β-cells resulting in calcium influx and subsequent insulin secretion (156). 
Sulfonylureas considerably lower blood glucose levels but involve the risk of 
hypoglycemia. Weight gain may aggravate insulin resistance (155). If either 
sulfonylureas or metformin alone fail to control blood glucose, a combination of 
both is established, partly in combination with a thiazolidinediones (152). 
Meglitinides (e.g. repaglinide) also stimulate insulin release in a manner similar to 
sulfonylureas, but are only short-lived, rendering the use of meglitinides suitable 
prior to meal. Side effects are similar to that of sulfonylureas but with lower risk 
of hypoglycaemia (155). 
Thiazolidinediones (TZDs, e.g. rosiglitazone, pioglitazone) act as insulin 
sensitizers by activation of the nuclear peroxisome-proliferator-activated receptor 
γ (PPAR γ). In the past years, TZDs commanded the majority of the global market 
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share (1). However, TZDs additionally provoke side effects that resulted in 
restriction of their use (157, 158). New concepts of PPARγ modulation offer a 
promising approach. Selective modulation of PPARγ (SPPARγM) and the other 
isotypes (dual and pan PPAR agonists) will improve the efficacy and safety 
profile of current PPARγ agonists (see 1.3.1.3). Several SPPARγMs and dual 
PPAR agonists showed minimized side effects like weight gain in clinical studies 
and thus are promising drugs for the treatment of diabetes and associated 
disorders (136). However, a lot of dual PPARα/PPARγ activators (glitazars) have 
been discontinued due to toxicity problems (138).  
The α-glucosidase inhibitors (e.g. acarbose) reduce digestion and uptake of 
carbohydrates by blocking intestinal α-glucosidase (1). Thus, postprandial 
hyperglycemia is reduced. The α-glucosidase inhibitors have less potent glucose-
lowering efficacy compared to the aforementioned agents but have a good safety 
profile (155). 
GLP-1 analogues and DPP-4 inhibitors are novel anti-diabetic drugs that affect 
the incretin system. Incretins such as GLP-1 (glucagon-like peptide 1) are secreted 
from colon cells shortly after food intake via activation of neuro-endocrine 
pathways. They act on the pancreatic β-cells by enhancing insulin release and 
production. GLP-1 is rapidly degraded by the ubiquitous dipeptidyl peptidase-4 
(DPP-4). Thus, the underlying mechanism is glucose-dependent and presents an 
attractive anti-diabetic target, since the risk of hypoglycaemia is minimized (155). 
GLP-1 analogues (exenatide, liraglutide) need parenteral administration and 
trigger insulin secretion in the presence of glucose. DPP-4 inhibitors (gliptins) are 
orally active and reversibly inhibit DPP-4. Both GLP-1 analogues and DPP-4 
inhibitors revealed a promising efficacy and safety profile so far and will a have a 
valuable role in future (1, 155).  
Amylin analogues (pramlintide) are occasionally injected in parallel to insulin and 
lower serum glucose by decreasing glucagon release, slowing gastric emptying, 
and decreasing food intake (159). 
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Due to the causative linkage between diabetes and obesity, it should be noted that 
only orlistat is currently applied as long-term obesity treatment. Orlistat inhibits 
intestinal lipoprotein lipase and thus reduces fat absorption and provokes weight 
loss (160). Unfortunately, the promising centrally acting anoretics sibutramine 
and rimonabant have been withdrawn due to side effects (160). 
Novel targets for the treatment of type 2 diabetes including 11β-hydroxysteroid 
dehydrogenase 1 (HSD11B1), G protein-coupled receptor 119 (GPR119), 
sodium/glucose cotransporters (SGLT1 and 2) and stearoyl-CoA desaturase 
(SCD) are described in plenty of current patent claims (161). 
 
1.5  Prevention of type 2 diabetes 
Considering the growing incidences of obesity and type 2 diabetes strategies for 
the prevention of metabolic disorders before their development are of central 
importance. Although obesity and insulin resistance are reversible to a certain 
condition (17), their progression lead to irreversible damages such as pancreatic β-
cell failure. It is obvious that a paradigm shift from treatment to prevention of 
metabolic diseases is required. As the pathogenesis of type 2 diabetes is causally 
linked to physical inactivity and hypercaloric diet (11, 17), changes in life style 
and nutrition are fundamental for health management. Classically, diet was 
characterized by its energy content, and the amount of calories was the major 
marker of healthy nutrition. In the past decades, it was recognized that specific 
molecular compounds can influence the metabolism, and that so called 
nutraceuticals, food-derived products with pharmaceutical benefits, add additional 
profits for reducing the risk for metabolic disorders (162). The emerging field of 
nutrigenomics aims to unravel the dietary impacts on metabolism and homeostatic 
control (163). Nuclear hormone receptors as PPARs have a key position therein, 
as they are nutrient sensors involved in energy homeostasis and metabolic 
disorders (164). Nuclear receptors can not only be activated by macronutrients 
(e.g. PPARs or LXRs by fats) and micronutrients (e.g. retinoic acid receptors by 
vitamin A), but further can be modulated by a magnitude of dietary small 
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molecules such as flavonoids and polyphenols. This is addressed by the 
application of functional foods, modified diets that hold beneficial effects on 
health, which gain increasing importance for the food industry (165). Recent 
innovative ingredients include cholesterol-lowering phytosterols, triglyceride-
reducing unsaturated fatty acids and chocolate enriched with blood-pressure-
lowering flavonoids (166). Several nutraceuticals have also been reported to 
reduce insulin resistance. For instance, vitamin D may increase insulin sensitivity 
(167) and also was shown to prevent the onset of diabetes (168). Additionally, 
soluble fibers such as glucomannan and chlorogenic acid decrease insulin 
resistance by slowing carbohydrate absorption similar to α-glucosidase inhibitors 
(see 1.4) (162, 169). Further improvement in insulin sensitivity was observed 
during studies with chromium, magnesium and α-lipoic acid (169). Since 2006 the 
European Food Safety Authority (EFSA) requires detailed scientific justification 
of health claims to avoid consumer misleading (170). The beneficial effects of 
nutraceuticals on diabetes and obesity therefore need additional clinical studies in 
healthy volunteers and/or diabetic patients. However, due to low long-term effects 
measuring preventive effects in healthy volunteers is more difficult than detecting 
therapeutic effects in diabetic patients. The future will show if nutraceutical 
companies will endeavour sophisticated long-term studies for prevention, or if 
anti-diabetic nutraceuticals will be primarily approved for co-treatment of insulin 
resistance.  
 
1.6  Mother Nature’s medicine chest - Natural products in drug discovery  
The current decline in new drug approvals and progressive loss of patent 
protection require new strategies for the development of new chemical entities 
(171). Natural products are still promising sources of new drugs, albeit their 
application for drug screening is regressive (171). Natural products are secondary 
metabolites, small molecules that are not essential for that organism. Often in 
form of crude plant extracts, natural products were the first drugs available to 
mankind and are still the major medicine worldwide (e.g. by Traditional Chinese 
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Medicine) (172). Natural products also played an essential role for the 
development of pharmacology in the Western world, as about half of the current 
approved drugs are based on natural products (173).  
For instance, statins used for the treatment of hypercholesterolemia are derivatives 
of the natural polyketide compactin (mevastatin), which was isolated from the 
mold Penicillium citrinum in 1976 (174). Of note, the derivative atorvastin 
(Lipitor) was the best selling drug in 2008 and brought about 12 billion US dollars 
annual sales (175). The widespread analgesic acetylsalicylic acid (Aspirin) has its 
origin in nature, too. Already the ancient Greek used extracts from willow bark to 
treat pain and fever, and 2000 years later the active natural product salicin was 
isolated and improved (176). Therapy of severe pain is often administered with 
morphine, which was discovered and isolated from opium in 1804 (177). Pain 
patients that are intolerant to morphine are alternatively treated with the peptide 
ziconotide (Prialt) derived from the marine cone snail conus magus (178). Also 
the popular antiphlogistics tacrolimus (FK506) and cyclosporine were isolated 
from bacterial and fungal sources, respectively (179, 180).  
Since combating microbial invaders is a major challenge for plants and fungi they 
evolved a huge amount of antibiotics that are also beneficial for human health 
management. Penicillin, isolated from the mould Penicillium notatum by 
Alexander Fleming in 1928 (181), and other β-lactam antibiotics play a pivotal 
role for the treatment of infections. Besides, artemisinin, isolated from the plant 
Artemisia annua, was established as standard medication of malaria (182). 
Moreover, treatment of cancer is a growing field in pharmacology. The taxanes 
(taxol) were first isolated from the Pacific yew tree Taxus brevifolia and are of 
major importance in chemotherapy of various types of cancer (183).  
Noteworthy, also some anti-diabetic drugs are natural products or analogues 
thereof. For instance, the development of the biguanide metformin was attributed 
to the isolation of guanides from Galega officinalis (French lilac), which was used 
because of its hypoglycemic properties for hundreds of years (184). Additionally, 
the novel GLP-1 analogue exenatide is a synthetic version of exendin-4, a 
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hormone found in the saliva of the Gila monster that was first isolated in 1992 
(185).  
But not only pure chemical compounds are used for the medication of common 
diseases. There is also a growing interest for the usage of mixtures of natural 
products based on traditional remedies. For instance, besides various bioactive 
plant extracts available without prescription (e.g. Saint John's wort extracts), a 
defined mixture of compounds extracted from green tea (sinecatechins, Veregen) 
was recently approved officially for the treatment of genital warts (173).  
These examples impressively illustrate the high potential of natural resources to 
combat disorders and to serve as leads for the development of derivatives. As 
natural sources, the current focus is on plant-, fungi- and actinomycetes-derived 
compound libraries. Though, collections of compounds from marine organism and 
cyanobacteria are increasingly investigated (171).  
Screening of natural product libraries has several advantages over the 
investigation of synthetic combinatorial libraries. In general, the success rate of 
natural product library screening is much higher (171), because natural products 
have a higher chance to interact with biological target molecules. This can be 
explained by the different structural properties of synthetic and natural 
compounds. There is a huge chemical space that can potentially be occupied by 
synthetic compounds. A theoretical library of compounds with up to 30 atoms 
(carbon, nitrogen, oxygen and sulfur) may contain more than 1060 different 
molecules (186). On the other hand, the chemical space of biological targets is 
modest in size – e.g. the human genome encodes about 25,000 genes (187). For 
the three-dimensional folding of proteins only a strict set for stable 
conformational interactions is allowed. The bottleneck of combinatorial chemistry 
is the lack of knowledge about the areas of chemical space that are suited to 
interact with biological space. On the other side, natural products are produced by 
proteins and thereby naturally interact with these biological molecules. 
Consequently, natural products can more likely interact with biological targets in 
a screening approach (171).  
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Several disadvantages of natural product library screening account for their 
decreased application in the pharmaceutical industry. Access and supply to the 
natural resources have to be assured, but are subjected to biological variation, risk 
of extinction and loss of biodiversity, political restrictions and intellectual 
property concerns (171, 173). In the process of high-throughput screening 
problems of purity, solubility and stability can occur. In addition, considerable 
time can be required for structural characterisation of novel natural products. 
Since many known natural products have already been patented, the driven force 
is reduced in many pharmaceutical organizations, leading to a drop in natural 
product-based drug development in the last years (171).  
However, only few microorganisms and plants have been examined for 
bioactivity. Advances in plants collections, microbe cultivation and systematic 
classification using the metagenomics approach, and development of new natural 
resources (e.g. marine organisms and insects) will provide many novel 
compounds. 
 
1.7  Aims of this thesis 
In consideration of the high pandemic prevalence of type 2 diabetes, new anti-
diabetic compounds are required for pharmaceutical and nutraceutical 
development. The nuclear receptor PPARγ is an important target for insulin 
sensitizing drugs, but treatment with current PPARγ-activating drugs is associated 
with severe side effects. The objective of this work was to identify and 
characterize novel PPARγ ligands. A large natural product library has to be 
screened with different biophysical and cellular approaches. For the screening hits 
potency and selectivity of PPARγ activation has to be characterized. In different 
cell models the influence of novel PPARγ modulators on gene expression has to 
be systematically investigated and compared to known PPARγ ligands. Effects on 
prevention and therapy of type 2 diabetes have to be further investigated in 
different mouse models. Various metabolic tests in mice, gene expression 
analyses and biochemical experiments in isolated tissues have to be performed. 
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The final aim is to discover a novel class of potent natural products that have 
promising in vivo properties for the application as pharmaceutical or nutraceutical 
compound for prevention or therapy of type 2 diabetes or other PPARγ-related 
diseases.  
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2  Materials and Methods 
2.1  Compounds and natural products  
Compounds were purchased from the following sources: rosiglitazone (Cayman, 
Biozol, Eching, Germany), nTZDpa (Tocris, Biozol, Eching, Germany), 
pioglitazone (Sigma Aldrich, Taufkirchen, Germany), telmisartan, troglitazone, 
GW0742, GW7647 (all from Sigma-Aldrich, Taufkirchen, Germany), 
amorfrutin 1 (NP-003520), amorfrutin 2 (NP-003521), amorfrutin 3 (NP-006430), 
amorfrutin 4 (NP-009525), other natural products including the natural product 
library (all available from Analyticon Discovery, Potsdam, Germany). We used a 
diverse library of natural products, consisting of approximately 8,000 compounds. 
It contained pure plant-derived and microbial metabolites representing a great 
variety of different substance classes and structures. Purity of natural compounds 
was determined by high performance liquid chromatography (HPLC) or nuclear 
magnetic resonance (NMR) spectroscopy and on average 95 % was achieved. 
Structural elucidation was performed by NMR and liquid chromatography 
coupled to mass spectrometry (LC/MS). The amorfrutins were isolated from roots 
of Glycyrrhiza foetida (approximately 3.5 g per kg plant material) and 
alternatively from fruits of Amorpha fruticosa (approximately 500 mg per kg 
plant material) using organic extraction and iterative HPLC separation of organic 
fractions. Amorfrutins 1, 5, and 5ME were additionally synthesized in-house as 
described below. 
 
2.2  Chemical synthesis of amorfrutins  
Investigation of the effects of amorfrutins in vivo required the development of a 
chemical synthesis to gain multigram quantities of compound. A synthesis route 
for the amorfrutins was developed by Dr. Frank C. Schroeder (Boyce Thompson 
Institute and Department of Chemistry and Chemical Biology, Cornell University, 
Ithaca, NY 14853, USA). Amorfrutins 1, 5, and 5ME were synthesized by Aman 
Prasad and Dr. Frank C. Schroeder with purities greater than 99%.  
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2.3  Time-resolved FRET assays 
Identified PPARγ ligands were validated and characterized by a time-resolved 
fluorescence resonance energy transfer (TR-FRET)-based competitive binding 
assay. FRET involves a radiationless energy transfer from stimulated electrons 
(s1) of a donor fluorophor to ground state electrons (s0) of an acceptor fluorophor, 
provided that the emission spectrum of the donor overlaps the excitation spectrum 
of the acceptor dye. The efficiency of the energy transfer is highly dependent on 
the intermolecular distance, so that a minimal spatial distance of the dyes of ca. 
8 nm is required (190). For time-resolved FRET lanthanide complexes are used as 
fluorescence donor. Lanthanides have long fluorescence life times (µs- to ms-
scale), and thus, their fluorescence can be detected after a certain time delay (e.g. 
200 µs), while the common short-lived background fluorescence is already 
decayed. This leads to an increased signal-to-background ratio. The common large 
Stokes shift of lanthanides further enhances the signal-to-background ratio. 
To characterize molecular binding to PPAR the LanthaScreen competitive binding 
assays (Invitrogen, Darmstadt, Germany) were used. This technology makes use 
of terbium-labelled anti-GST-antibodies bound to GST-tagged PPAR and 
fluorescein-labelled dexamethasone. Increasing the concentration of potential 
ligands results in displacement of the labelled PPAR-ligand and hence in a 
decrease of the TR-FRET signal.  
To determine ligand-induced cofactor recruitment to PPAR the LanthaScreen 
coactivator assays (Invitrogen, Darmstadt, Germany) were used. This approach 
involves terbium-labelled anti-GST-antibodies bound to GST-tagged PPAR and 
fluorescein-labelled cofactor peptides. Increasing the concentration of ligands 
leads to conformational change of PPAR and thus to enhanced or decreased 
binding of labelled cofactor peptides observed as change in the TR-FRET signal. 
This experiment not only discloses the ligand’s effective concentrations, but 
further elicits the ligand-specific recruitment efficacy, that means the degree of 
cofactor association at PPARγ/ligand-saturated conditions. The efficacy thus is 
the maximal magnitude of cofactor recruitment achievable with this ligand. 
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Experiments were performed according to the manufacturer’s protocols. To save 
resources the assays were miniaturized to a final volume of 5 to 10 µl end volume 
without loss in performance as determined by a Z’-factor > 0.7 (191). Competitive 
binding was measured in black small volume high bind polystyrene 384-well 
plates (Greiner Bio-One, Frickenhausen, Germany). Cofactor recruitment was 
detected in black low volume non-treated polystyrene 384-well plates (Corning 
Life Sciences, Fisher Scientific, Schwerte, Germany). The terbium chelate was 
excited at 340 nm and fluorescence was measured after 200 µs over 100 µs at 
490 nm for terbium and at 520 nm for fluorescein. Fluorescence was measured 
with the POLARstar Omega (BMG LABTECH, Offenburg, Germany). For FRET 
calculation relative fluorescence units for 520 nm were divided by 490 nm.  
Data were fitted using GraphPad Prism 5.0. Competitive binding data were fitted 
according to equation:  
Y=Top + (Bottom - Top)/(1+10^((LogIC50-X)*HillSlope))  
with variable Hill slope. ‘Y’ means FRET ratio (520nm/490nm), ‘X’ is titrated 
ligand concentration in logarithmic unit, ‘Bottom’ and ‘Top’ represent the 
plateaus in the units of the FRET ratio, Hill slope describes the steepness of the 
curve, and ‘IC50’ is the ligand concentration at 50% binding that has to be 
determined. IC50 values were converted to general Ki values according to Cheng 
and Prusoff (192). Cofactor recruitment data were fitted according to equation:  
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)).  
‘EC50’ is the ligand concentration at 50% cofactor binding. Efficacy (‘Top’) of 
cofactor recruitment is normalized to the full PPARγ agonist rosiglitazone (set to 
100%).  
 
2.4  Reporter-gene assay 
Reporter gene assays allow the verification and characterization of PPARγ 
agonists in a cellular environment, but are limited by artificial overexpression of 
the chimeric PPARγ-construct and by very simplified promoter architecture. 
Cellular activation of PPARγ was assessed in a reporter gene assay according to 
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the manufacturer’s protocol (GeneBLAzer PPARγ DA Assay, Invitrogen). In 
brief, HEK 293H cells stably express a GAL4-PPARγ-LBD fusion protein and an 
UAS-beta-lactamase reporter gene. Upon binding on the PPARγ-LBD the ligand 
induces transcriptional activity of the fusion protein. This leads to expression of 
beta-lactamase, which subsequently catalyzes the cleavage of a fluorophor that 
consists of a coumarin (donor) and a fluorescein (acceptor) molecule linked by a 
lactam moiety. After cleavage both fluorophores become separated, resulting in a 
decrease of FRET efficiency. Thus, PPARγ activation is detected by an increase 
in coumarin fluorescence.   
Cells were incubated with indicated concentrations of compounds. FRET was 
measured in a black polystyrene cell culture 384-well plate (Corning Life 
Sciences) in the POLARstar Omega with excitation at 410 nm and emission at 
460 and 530 nm. For FRET calculation relative fluorescence units for 530 nm 
were divided by 460 nm. Obtained data were fitted using GraphPad Prism 5.0 
according equation:  
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))  
with variable Hill slope. Efficacy (‘Top’) of PPARγ activation is normalized to 
the full PPARγ agonist rosiglitazone (set to 100%).  
 
2.5  Crystallization and structure determination  
Crystallization and structure determination of the human ligand binding domain of 
PPARy in complex with amorfrutin 1 was kindly done by Jens C. de Groot and 
Dr. Konrad Büssow (Division of Structural Biology, Helmholtz Centre for 
Infection Research, Braunschweig, Germany). Briefly, crystallization was 
performed using hanging drop-vapour phase diffusion. The structure was solved 
by molecular replacement with PDB entry 1PRG (193) and refined to a resolution 
of 2.0 Ǻ.  
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2.6  Cell culture 
Gene expression studies were performed in adipocytes, in which PPARγ is highly 
expressed. Mouse 3T3-L1 cells (kindly provided by Dr. Schürmann, DifE, 
Potsdam-Rehbrücke, Germany) were cultured in Dulbecco's modified Eagle's 
medium (DMEM, Invitrogen) and 10% calf bovine serum (ATCC, LGC 
Promochem, Wesel, Germany) prior differentiation. Two-day post-confluent cells 
were differentiated in DMEM supplemented with 10% fetal bovine serum (FBS, 
Biochrom, Berlin, Germany), 10 µg/ml human insulin, 1 µM dexamethasone and 
500 µM 3-isobutyl-1-methylxanthine (all Sigma-Aldrich). After 2 days of 
differentiation, medium was changed to DMEM supplemented with 10% FBS and 
10 µg/ml human insulin for additional 2 days. Thereafter, cells were maintained in 
DMEM/10% FBS for 4 days with medium change every other day. To investigate 
the compound effects on PPARγ target genes, differentiated adipocytes were 
incubated for 24 hours with indicated amounts of substances, whereas 0.1% 
DMSO was used as vehicle control.  
Primary subcutaneous preadipocytes isolated from human patients were provided 
by Zen-Bio (BioCat, Heidelberg, Germany). Cells were differentiated and 
modified after the manufacturer’s protocol. Briefly, preadipocytes were 
maintained on nunclon plates (Nunc, Wiesbaden, Germany) in preadipocyte 
medium (PM-1, Zen-Bio) until differentiation. Cells were differentiated using 
PPARγ agonist-free adipocyte medium (AM-1, Zen-Bio) supplemented with 500 
µM IBMX for 7 days. Thereafter, medium was changed to pure AM-1 for 
additional 7 days. Mature adipocytes were treated with indicated compounds 
diluted in AM-1 for 24 hours, whereas 0.1% DMSO was used as vehicle control. 
 
2.7  PPARγ knockdown  
Specificity of compound-dependent gene expression effects was investigated in 
siRNA-mediated PPARγ knockdown in adipocytes with subsequent qPCR 
analysis. Therefore, differentiated human adipocytes were seeded in 24-well-
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plates at a confluence of 30 to 60%. Cells were transfected with 10 nM PPARγ 
Silencer Select Validated siRNA (ID s10888) or 10 nM Silencer Select Negative 
Control #1 siRNA (all Ambion, Applied Biosystems) using DeliverX Plus siRNA 
Transfection Kit (Panomics, BioCat). Transfection was carried out in serum- and 
antibiotic-free AM-1 medium (AM-1-PRF-SF, Zen-Bio) for 4 hours and 
continued for 3 days in standard AM-1 medium. Afterwards, compounds and 
vehicle control were added to PPARγ-knockdown and negative control cells for 
24 hours. 
 
2.8  RNA purification, cDNA synthesis and qPCR 
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN) according to their 
manual. For gene expression analysis in mice, tissues were first lysed and 
homogenized in RLT buffer (QIAGEN) with 5 mm steel beads at 20 Hz for 4 min 
(TissueLyser, QIAGEN). Genomic DNA was digested on column using the 
DNase-Set (QIAGEN). The concentration of extracted RNA was measured using 
the Nanodrop ND-1000 Spectrophotometer (Fisher Scientific). RNA was 
reversely transcribed into cDNA applying the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) with random primers. 
Quantitative real-time PCR (qPCR) was carried out on the ABI Prism 7900HT 
Sequence Detection System using the SYBR Green PCR Master Mix (Applied 
Biosystems) to investigate the effects of natural products on PPARγ target gene 
expression. Briefly, after an initial denaturation at 95 °C for 10 min, the cDNA 
was amplified by 40 cycles of PCR (95 °C, 15 s; 60 °C, 60 s). The relative gene 
expression levels were normalized using β-actin gene and quantified by the 2-∆∆Ct 
method (194). If not otherwise denoted, primers were designed with the Primer3 
software (195) following specificity check with NCBI BLAST search (196). 
Primers with following sequences were used. 
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Symbol Species Forward primer Reverse primer Ref. 
ACTB human CAGCCATGTACGTTGCTATCCAGG AGGTCCAGACGCAGGATGGCATG   
ADIPOQ human GGTGAGAAGGGTGAGAAAGG TCCTTTCCTGCCTTGGATT   
CD36 human GTTGATTTGTGAATAAGAACCAGAGC TGTTAAGCACCTGTTTCTTGCAA   
FABP4 human GGTGGTGGAATGCGTCATG CAACGTCCCTTGGCTTATGC   
HSD11B1 human GGCCTCATAGACACAGAAACAGC TGATCTCCAGGGCACATTCC   
LPL human ACAGAATTACTGGCCTCGATCC CTGCATCATCAGGAGAAAGACG   
NR1H3 human CACCTACATGCGTCGCAAGT GACAGGACACACTCCTCCCG   
PLTP human GACACCGTGCCTGTGCG GGTGGAAGCCACAGGATCCT   
PPARG human CATGGCAATTGAATGTCGTGTC CCGGAAGAAACCCTTGCAT   
PPIB human ACGACAGTCAAGACAGCCTGG CTTCCGCACCACCTCCAT   
Acadl mouse AGCCTGGGGCTGGAAGTGACTTA CACGGTTGGTGACGGCCACG   
Acly mouse CAGCCAAGGCAATTTCAGAGC CTCGACGTTTGATTAACTGGTCT (147)  
Acox1 mouse CAGCACTGGTCTCCGTCATG CTCCGGACTACCATCCAAGATG   
Actb mouse TGTCCACCTTCCAGCAGATGT AGCTCAGTAACAGTCCGCCTAGA  
Aplp2 mouse GTGGTGGAAGACCGTGACTAC TCGGGGGAACTTTAACATCGT (147)  
Car3 mouse TGACAGGTCTATGCTGAGGGG CAGCGTATTTTACTCCGTCCAC (147) 
Ccl2 mouse CCAGCACCAGCACCAGCCAA TGGGGCGTTAACTGCATCTGGC   
Ccl3 mouse GCTCCCAGCCAGGTGTCATTTTCC GGGGTTCCTCGCTGCCTCCA   
Ccl5 mouse CTCACTGCAGCCGCCCTCTG CCGAGCCATATGGTGAGGCAGG   
Ccr2 mouse TCAGCTGCCTGCAAAGACCAGA CGGTGTGGTGGCCCCTTCAT   
Ccr5 mouse AGACTCTGGCTCTTGCAGGATGGA GGCAGGAGCTGAGCCGCAAT   
Cd24a mouse GTTGCACCGTTTCCCGGTAA CCCCTCTGGTGGTAGCGTTA (147) 
Cfd mouse CATGCTCGGCCCTACATGG CACAGAGTCGTCATCCGTCAC (147) 
Cidec mouse ATGGACTACGCCATGAAGTCT CGGTGCTAACACGACAGGG (147) 
Cpt1a mouse TCTGCAGACTCGGTCACCACTCAAG GGCTCAGGCGGAGATCGATGC   
Cpt2 mouse AAGCAGCGATGGGCCAG GAGCTCAGGCAGGGTGACC   
Cxcl1 mouse GAGCTGCGCTGTCAGTGCCT TGTGGCTATGACTTCGGTTTGGGT   
Cyp2f2 mouse GTCGGTGTTCACGGTGTACC AAAGTTCCGCAGGATTTGGAC (147) 
Ddx17 mouse TCTTCAGCCAACAATCCCAATC GGCTCTATCGGTTTCACTACG (147) 
Emr1 mouse ACCCTCCAGCACATCCAGCCAA TCACAGCCCGAGGGTGTCCA   
Fabp4 mouse TGATGCCTTTGTGGGAACCT GCAAAGCCCACTCCCACTT   
Il1b mouse CCCTGCAGCTGGAGAGTGTGGA GCTCTGCTTGTGAGGTGCTGA   
Il6 mouse TCTGCAAGAGACTTCCATCCAGTTGC AGGCCGTGGTTGTCACCAGC   
Lgals3 mouse TGGGGCCTACCCCAGTGCTC GGCACCGTCAGTGGTCCAGC   
Nr1d1 mouse TACATTGGCTCTAGTGGCTCC CAGTAGGTGATGGTGGGAAGTA (147) 
Nr1d2 mouse TGAACGCAGGAGGTGTGATTG GAGGACTGGAAGCTATTCTCAGA (147) 
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Nr1h3 mouse GCTCTGCTCATTGCCATCAG  TGTTGCAGCCTCTCTACTTGGA    
Nr3c1 mouse AGCTCCCCCTGGTAGAGAC GGTGAAGACGCAGAAACCTTG (147) 
Peg10 mouse TGCTTGCACAGAGCTACAGTC AGTTTGGGATAGGGGCTGCT (147) 
Pgc1a mouse TCCCATACACAACCGCAGTCGC GGGGTCATTTGGTGACTCTGGGGT   
Ptgs2 mouse CCCTGCTGCCCGACACCTTC CCAGCAACCCGGCCAGCAAT   
Rarres2 mouse GCCTGGCCTGCATTAAAATGG CTTGCTTCAGAATTGGGCAGT (147) 
Rybp mouse CGACCAGGCCAAAAAGACAAG CACATCGCAGATGCTGCATT (147) 
Selenbp1 mouse ATGGCTACAAAATGCACAAAGTG CCTGTGTTCCGGTAAATGCAG (147) 
Slc2a4 mouse GCGGATGCTATGGGTCCTTA GTCCGGCCTCTGGTTTCA   
Tbl1x mouse CACAAGTTGCACGGCTCGCG AGTGTGAGCCACCCTCGTCACA   
Tnf mouse AGCCCACGTCGTAGCAAACCA CATGCCGTTGGCCAGGAGGG   
Txnip mouse TCTTTTGAGGTGGTCTTCAACG GCTTTGACTCGGGTAACTTCACA (147) 
 
2.9  Viability assays 
Cytotoxic effects of the natural products were assessed in HepG2 and 3T3-L1 
cells cultured in DMEM/10%FCS using the WST-1 reagent (Roche) according to 
the manufacturer’s protocol. Cells were incubated with different concentrations of 
compounds for 24 h. Experiments were performed in triplicate. 
 
2.10  Genome-wide gene expression analyses  
RNA quality was determined using the Bioanalyzer 2100 (Agilent). Biotin-
labelled cRNA was produced using the Illumina TotalPrep RNA Amplification 
Kit (Ambion) following the manufacturer’s instructions. Cy3-stained cRNA was 
hybridised on HumanHT-12 v3.0 or MouseWG-6 v2.0 Expression BeadChips 
(Illumina, Eindhoven, The Netherlands). Scanning was performed using the 
Illumina BeadStation 500 platform and reagents were used according to the 
protocols supplied by the manufacturer. Samples were hybridised at least in 
biological triplicates. All basic expression data analysis was carried out using 
BeadStudio 3.1 (Illumina). Raw data were background-subtracted and normalized 
using the cubic spline algorithm. Processed data were then filtered for significant 
detection (P value ≤ 0.01) and differential expression vs. vehicle treatment 
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according to the Illumina t-test error model and were corrected according to the 
Benjamini-Hochberg procedure (P value ≤ 0.05) in the Beadstudio software. Gene 
expression data were submitted in MIAME-compliant form to the Gene 
Expression Omnibus database (GSE28384). Heatmaps and hierarchical clustering 
of samples were carried out with Mayday 2.8 (197). K-Means clustering of genes 
was calculated with Euclidean distance in MeV 4.3. Genes from these clusters 
were checked for functional annotation enrichment using DAVID 2008 (198, 
199). Enrichment scores > 1.0 were considered as significant. 
A common disadvantage of singular gene analysis is attributed to the use of 
stringent filtering. Consequently, small expression changes of several genes 
important for a certain pathway are lost during analysis, although the overall 
pathway might be significantly regulated. This concern was addressed by the 
development of Gene Set Enrichment Analysis (GSEA) (200), which tests for 
enrichment of whole sets of genes (e.g. pathways) instead of single genes. GSEA 
was performed using the following parameters: 1000 gene set permutations, 
weighted enrichment statistic, and signal-to-noise metric. Microarray data were 
analyzed using the curated C2 gene sets from the Molecular Signature Database 
(MSigDB) including KEGG pathways and data from chemical and genetic 
perturbation experiments (version 2.5, 1892 gene sets) if not otherwise denoted.  
The high-dimensionality of whole-genome expression analyses is a problem for 
visualization and investigation of biologically relevant data. Principal component 
analysis (PCA) is often used for microarray data to reduce the dimensionality of 
the data while retaining most of the variation in the data set. Each compound 
profile is represented by few principal components instead of thousands of values. 
Thus, PCA allows for comparison of compound effects on genome-wide 
expression in a clearly arranged plot (201). PCA was performed in MeV 4.3 (202) 
using median centering. Principal components were calculated based on the mean 
expression profile of rosiglitazone, pioglitazone, nTZDpa and telmisartan and 
non-averaged sample profiles of amorfrutins. Principal components were then 
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averaged and plotted onto the axis with error bars representing standard 
deviations.  
In contrast to PCA, gene distance matrix (GDM) analyses include all gene 
expression data of a compound, without restriction to a set of genes. Data 
reduction is achieved by collapsing the expression data of every gene to a vector 
sum in Euclidean space. The Euclidean distance between the vector sums of 
different compounds therefore is a measure of the similarity between the 
expression profiles. GDM comparison was performed in MeV 4.3.  
Comparison of gene expression profiles of diseases or treatments with different 
small molecules reveals further insight into their mechanisms. The Connectivity 
Map approach provides a database of gene expression profiles of cells treated with 
small molecules and a pattern-matching software for expression data comparison 
(203, 204). To unravel the mechanism of action of identified PPARγ ligands we 
therefore compared the gene lists observed for rosiglitazone and amorfrutin 1 
treatment to published data (Connectivity Map build 02).  
 
2.11  Animal studies 
Animal studies have been validated and approved State Office of Health and 
Social Affairs Berlin (LAGeSo) and were carried out according internationally 
approved guidelines. All animals were maintained one per cage under 
temperature-, humidity- and light-controlled conditions (22°C, 50% humidity, 12 
hours light/12 hours dark-cycle). Mice had ad libitum access to food and water. 
Mice and food were weighed in a regularly manner to determine changes in body 
weight and food intake. 
To explore the potential of our compound of interests in the prevention of diabetes 
we designed a long-term and low-dose study in C57BL/6 mice. Therefore, male 
C57BL/6 mice at age of 9 weeks were weighed and distributed equally to 4 
groups (n=12). Mice were fed over 15 weeks with either low-fat diet (LFD, 
D12450B, 10 kcal% fat, ssniff, Soest, Germany), high-fat diet (HFD, D12492, 60 
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kcal% fat, ssniff) or high-fat diet with 4 mg/kg/d rosiglitazone (HFD+R) or 
37 mg/kg/d amorfrutin 1 (HFD+A1). After 8 weeks of dosing blood was taken 
from the submandibular vein of conscious mice for testing of blood parameters. 
After 10 weeks an oral glucose tolerance test (OGTT) was carried out. Mice were 
fasted overnight before being subjected to an oral dose of 2 g/kg body weight of 
glucose (Sigma-Aldrich). Blood was taken from tail vein at the indicated time 
points. Blood glucose was analysed in a Hemocue B-Glucose analyser (Hemocue, 
Großostheim, Germany). Blood was collected using Microvette lithium-heparin 
coated capillary tubes (CB300, Sarstedt, Nürnbrecht, Germany). After 
centrifugation for 5 min at 2,000g, 4 °C, plasma was collected and analysed for 
metabolic parameters. After 13 weeks of feeding an intraperitoneal insulin 
sensitivity test (IPIST) was performed. Mice were fasted overnight and then had 
ad libitum access to food for 1 hour before the test. One U/kg body weight of 
insulin was injected intraperitoneally. Blood was taken from tail vein at the 
indicated time points. After 15 weeks of dosing, fasted mice were killed by 
cervical dislocation. Plasma and tissues were collected and stored at -80 °C before 
use.  
For the therapy study we subjected diet-induced obesity (DIO) mice to a short-
term-medium-dose treatment. Male C57BL/6 mice at age of 6 weeks were fed 
with high fat diet (HFD) for 12 weeks to induce obesity and insulin resistance. 
The mice were then weighed and distributed equally to 3 groups (n=13 each). 
Mice were fed over 3 weeks with HFD without compound (vehicle), HFD with 
4 mg/kg/d rosiglitazone or with 100 mg/kg/d amorfrutin 1. After 17 days of 
treatment, an OGTT (2g/kg glucose) and after 23 days an IPIST (1.5 U/kg insulin) 
were performed as described above. After 24 days of dosing fasted mice were 
killed by cervical dislocation. Plasma and tissues were collected and stored at -
80 °C before use. 
To test the compounds in another diabetic model, leptin receptor deficient db/db 
mice (Charles River Laboratories, Sulzfeld, Germany) at age of 9 weeks were fed 
with standard diet (V1324, ssniff) without compound (vehicle), with 4 mg/kg/d 
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rosiglitazone or 100 mg/kg/d amorfrutin 1 over 3 weeks. After 17 days of 
treatment an IPIST (2.0 U/kg insulin) was carried out, and after 23 days an OGTT 
(2 g/kg glucose) was performed as described above. After 25 days of dosing 
fasted mice were killed by cervical dislocation. Plasma and tissues were collected 
and stored at -80 °C before use. 
 
2.12  Metabolic parameters measurements  
Plasma was used for the analysis of blood parameters. Glucose was measured 
using the Amplex Red Glucose Assay Kit (Invitrogen), while triglycerides, free 
fatty acids and plasma alanine transaminase (ALT) were determined with 
colorimetric quantification kits (Biovision, BioCat). Proinsulin, insulin and leptin 
were determined with mouse ELISA (Proinsulin Mouse ELISA and Insulin 
Ultrasensitive EIA, ALPCO, Immundiagnostik, Bensheim, Germany; Mouse 
Leptin ELISA, BioVendor, Heidelberg, Germany, respectively). All assays were 
performed according to the manufacturer’s instructions. HOMA-IR was 
determined according to ref. (205). 
For determining liver TNFα concentrations, murine liver (100 mg/ml) was lysed 
in a tissue lysis buffer (206) containing 20 mM Tris, 150 mM NaCl, 1 % 
Nonidet P-40, 0.5 % sodium deoxycholate, 1 mM EDTA, 0.1 % SDS and protease 
inhibitor cocktail (Roche). Samples were lysed and homogenized using disruption 
with 5 mm steel beads at 20 Hz for 4 min (TissueLyser, QIAGEN). After 
centrifugation for 10 min at 20,000 g, 4 °C, the supernatants were collected and 
used for TNFα ELISA (TNFα ELISA Ready-SET-Go, eBioscience, NatuTec, 
Frankfurt, Germany). The assay was miniaturized to a sample incubation volume 
of 25 µl and performed on a clear high bind polystyrene 384-well plate (Corning 
Life Sciences). For normalization of samples DNA content was measured using 
PicoGreen assay (Quant-iT, Invitrogen).  
To measure liver and pancreatic triglycerides, tissues were weighed and disrupted 
at a concentration of 44 mg/ml in 100 % isopropanol for liver or 100 mg/ml in 
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50 % isopropanol/PBS (pH 7.4) for pancreas. Disruption was performed with 
5 mm steel beads at 20 Hz for 4 min (TissueLyser). After centrifugation for 
10 min at 20,000 g, 4 °C, the supernatants were collected and measured in the 
colorimetric assay (Biovision). 
For the determination of glycogen in liver, tissues were weighed and disrupted at 
a concentration of 28 mg/ml in 200 mM sodium acetate (pH 4.8) using 5 mm steel 
beads at 20 Hz for 4 min (TissueLyser). The glycogen determination protocol 
(207) was modified as follows. Briefly, tissue lysates were heated to 70 °C for 
10 min to inactivate endogenous enzymes. Samples were centrifuged for 10 min 
at 6,000 g, 4 °C. Subsequently, 3 µl of sample supernatants were added to 57 µl of 
27 U/ml amyloglucosidase (Sigma-Aldrich) in 200 mM sodium acetate (pH 4.8) 
and incubated at 41 °C for 2 hours. To determine the free glucose in liver this 
incubation was also done with 3 µl of sample supernatant and 57 µl of 200 mM 
sodium acetate (pH 4.8) without amyloglucosidase. After incubation all samples 
were neutralized with 15 µl of 280 mM sodium hydroxide solution. Digested 
samples with or without enzyme were measured with the glucose assay kit 
(Invitrogen). For the calculation of liver glycogen, free glucose was subtracted 
from total glucose of each liver sample. Liver glycogen was presented as nmol 
released glucose per mg tissue. 
 
2.13  Immunoblotting  
To determine PPARγ phosphorylation vWAT of HFD-fed mice was lysed in 
UEES lysis buffer (9 M Urea, 100 mM EDTA/EGTA, 4% SDS with protease and 
phosphatase inhibitors) using 5 mm steel beads at 20 Hz for 4 min (TissueLyser). 
After centrifugation for 10 min at 10,000 g, the supernatants were stored at -80 °C 
until use. Samples were denatured and separated using a NuPAGE Novex 4-12% 
Bis-Tris gel (Invitrogen) and blotted onto nitrocellulose membranes. Membrane 
was blocked with a solution containing 2.5% milk powder, 2.5% BSA in PBS-T 
(0.05%) and 0.5x phosphatase inhibitor for 1 hour at room temperature. 
Membranes were washed in PBS-T (0.05%). A rabbit polyclonal phospho-specific 
Materials and Methods - 48  
antibody against PPARγ Ser 273 was produced by Eurogentech (Seraing, 
Belgium) with the phosphopeptide Ac-KTTDKpSPFVIYDC-amide (147). For 
detection, 0.8 µg/mL PPARy-pSer273 and 0.5 µg/mL PPARy (E-8, Santa Cruz, 
Heidelberg, Germany) antibody, respectively, were diluted in PBS-T (0.05%) 
with 1.5% milk powder and 1.5% BSA. Membranes were shaked overnight at 4°C 
and subsequently incubated with anti-rabbit IgG-HRP (Santa Cruz, sc-2004) and 
anti-mouse IgG-HRP (Santa Cruz, sc-2005), respectively, prior to detection with 
Western Lightning ECL solution (Perkin Elmer) on a Fujifilm LAS-1000 camera 
system using the Image Reader LAS-1000 Pro V2.61 software. Membranes were 
stripped with Restore Plus Western Blot Stripping Buffer (Thermo Scientific) for 
10 min. Densitometry was performed in ImageQuant TL (GE Healthcare). The 
rate of PPARy phosphorylation was normalized to total PPARy protein. 
 
2.14  Statistical analyses 
Data are presented as mean ± standard error of mean (s.e.m.) if not otherwise 
denoted. Statistical significance was determined by unpaired two-tailed Student’s 
t-test for single comparisons and one-way ANOVA with Dunnett’s post test for 
multiple comparisons using GraphPad Prism 5.0. Pearson correlation analyses 
were performed in GraphPad Prism 5.0. A P-value ≤ 0.05 was defined as 
statistically significant. 
 
2.15  Equipment and reagents 
2.15.1 Reagents 
Reagent Manufacturer/Provider 
DMSO Merck (Darmstadt, Germany) 
Natural products AnalytiCon Discovery (Potsdam, Germany) 
Amorfrutin 1 (synthetic) Kindly provided by Dr. Frank C. Schroeder (Cornell University, Ithaca, USA) 
Amorfrutin 5 Kindly provided by Dr. Frank C. Schroeder (Cornell University, Ithaca, USA) 
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Amorfrutin 5ME Kindly provided by Dr. Frank C. Schroeder (Cornell University, Ithaca, USA) 
GW0742 Sigma-Aldrich (Taufkirchen, Germany) 
GW7647  Sigma-Aldrich (Taufkirchen, Germany) 
nTZDpa  Tocris (Biozol, Eching, Germany) 
Pioglitazone  Sigma-Aldrich (Taufkirchen, Germany) 
Rosiglitazone  Cayman (Biozol, Eching, Germany) 
Telmisartan Sigma-Aldrich (Taufkirchen, Germany) 
Troglitazone Sigma-Aldrich (Taufkirchen, Germany) 
Amplex Red Glucose Assay Kit Invitrogen (Karlsruhe, Germany) 
Amyloglucosidase (A1602)  Sigma-Aldrich (Taufkirchen, Germany) 
FFA quantification kit Biovision (Biocat, Heidelberg, Germany) 
Triglyceride quantification kit Biovision (Biocat, Heidelberg, Germany) 
Lanthascreen PPARa competitive binding 
assay (PV4892) Invitrogen (Karlsruhe, Germany) 
Lanthascreen PPARb/d competitive binding 
assay (PV4893) Invitrogen (Karlsruhe, Germany) 
Lanthascreen PPARγ competitive binding 
assay (PV4894) Invitrogen (Karlsruhe, Germany) 
Lanthascreen PPARγ Coactivator Assay  
(PV4548) Invitrogen (Karlsruhe, Germany) 
Lanthascreen Fl-CBP-1 Peptide (PV4596) Invitrogen (Karlsruhe, Germany) 
Lanthascreen Fl-NCOR ID2 Peptide 
(PV4624) Invitrogen (Karlsruhe, Germany) 
Lanthascreen Fl-PGC1A Peptide (PV4421) Invitrogen (Karlsruhe, Germany) 
Lanthascreen Fl-PRIPRAP250 Peptide 
(PV4604) Invitrogen (Karlsruhe, Germany) 
GeneBLAzer PPARγ DA Assay (K1419) Invitrogen (Karlsruhe, Germany) 
Mouse Insulin Ultrasensitive EIA ALPCO (Immundiagnostik, Bensheim, Germany) 
Mouse Leptin ELISA BioVendor (Heidelberg, Germany) 
Mouse Proinsulin EIA ALPCO (Immundiagnostik, Bensheim, Germany) 
Mouse TNFα ELISA Ready-SET-Go eBioscience (NatuTec, Frankfurt, Germany) 
ALT Assay Kit Biovision (Biocat, Heidelberg, Germany) 
Dulbecco's modified Eagle's medium 
(DMEM) ATCC (LGC Promochem, Wesel, Germany) 
Preadipocyte medium (PM-1) Zen-Bio (BioCat, Heidelberg, Germany) 
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Adipocyte medium (AM-1) Zen-Bio (BioCat, Heidelberg, Germany) 
Serum- and antibiotic-free AM-1 medium 
(AM-1-PRF-SF) Zen-Bio (BioCat, Heidelberg, Germany) 
Phosphate buffered saline solution (PBS), pH 
7.4 GIBCO (Invitrogen, Karlsruhe, Germany) 
Calf Serum (CS) ATCC (LGC Promochem, Wesel, Germany) 
Fetal Calf Serum superior (FCS) Biochrom (Berlin, Germany) 
TrypLE Express GIBCO (Invitrogen, Karlsruhe, Germany) 
Trypan Blue Stain Invitrogen (Karlsruhe, Germany) 
3-Isobutyl-1-methylxanthine (IBMX) Sigma-Aldrich (Taufkirchen, Germany) 
Dexamethasone Sigma-Aldrich (Taufkirchen, Germany) 
WST-1 Roche (Mannheim, Germany) 
DeliverX Plus siRNA Transfection Kit  Panomics (BioCat, Heidelberg, Germany) 
PPARγ Silencer Select Validated siRNA (ID 
s10888)  
Ambion (Applied Biosystems, Darmstadt, 
Germany) 
Silencer Select Negative Control #1 siRNA  Ambion (Applied Biosystems, Darmstadt, Germany) 
Ethanol Merck (Darmstadt, Germany) 
Isopropanol Merck (Darmstadt, Germany) 
RNase-free water Ambion (Applied Biosystems, Darmstadt, Germany) 
TRIzol reagent Invitrogen (Karlsruhe, Germany) 
β-Mercaptoethanol Sigma-Aldrich (Taufkirchen, Germany) 
RNeasy Plus Mini Kit QIAGEN (Hilden, Germany) 
DNase set QIAGEN (Hilden, Germany) 
High Capacity cDNA Reverse Transcription 
Kit  Applied Biosystems (Darmstadt, Germany) 
Illumina TotalPrep RNA Amplification Kit  Ambion (Applied Biosystems, Darmstadt, Germany) 
SYBR GREEN PCR Master Mix Applied Biosystems (Darmstadt, Germany) 
Real-time PCR Primer Sigma-Aldrich (Taufkirchen, Germany) 
Picogreen Quant-iT Invitrogen (Karlsruhe, Germany) 
Animal diets ssniff (Soest, Germany) 
Glucose  Sigma-Aldrich (Taufkirchen, Germany) 
Insulin solution (human) Sigma-Aldrich (Taufkirchen, Germany) 
Urea Sigma-Aldrich (Taufkirchen, Germany) 
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Sodium dodecyl sulfate (SDS) Sigma-Aldrich (Taufkirchen, Germany) 
Tween-20 Sigma-Aldrich (Taufkirchen, Germany) 
1x Phosphatase Inhibitor Cocktail  Sigma-Aldrich (Taufkirchen, Germany) 
1x Protease Inhibitor Cocktail  Roche (Mannheim, Germany) 
Tris(hydroxymethyl)aminomethane (Tris) Sigma-Aldrich (Taufkirchen, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (Taufkirchen, Germany) 
Ethyleneglycoltetraacetic acid (EDTA) Sigma-Aldrich (Taufkirchen, Germany) 
Coomassie Brillant Blue R250 Bio-Rad Laboratories (München, Germany) 
Precision Plus Protein all blue standards Bio-Rad Laboratories (München, Germany) 
Milk powder  Sigma-Aldrich (Taufkirchen, Germany) 
Bovine serum albumin (BSA) Sigma-Aldrich (Taufkirchen, Germany) 
Anti-PPARy antibody (E-8, mouse 
monoclonal) Santa Cruz (Heidelberg, Germany) 
Anti-pSer273-PPARy antibody (rabbit 
polyclonal) Eurogentech (Seraing, Belgium) 
Anti-mouse IgG-HRP (sc-2005, goat) Santa Cruz (Heidelberg, Germany) 
Anti-rabbit IgG-HRP (sc-2004, goat) Santa Cruz (Heidelberg, Germany) 
Restore Plus Western Blot Stripping Buffer  Pierce (Fisher Scientific, Schwerte, Germany) 
Western Lightning ECL solution  Perkin Elmer (Rodgau, Germany) 
 
2.15.2 Cells and animals 
Cell/Animal model Provider 
3T3-L1 cell line Kindly provided by Dr. Schürmann (DIfE, Nuhtetal, Germany) 
HepG2 cell line ATCC (LGC Promochem, Wesel, Germany) 
Human primary preadipocytes Zen-Bio (BioCat, Heidelberg, Germany) 
C57BL/6 mice In-house breeding 
db/db mice  Charles River Laboratories (Sulzfeld, Germany) 
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2.15.3 Equipments and consumables 
Product Manufacturer 
384 Well Flat Bottom Polystyrene High Bind 
Microplate, clear (3700) 
Corning Life Sciences (Fisher Scientific, 
Schwerte, Germany) 
384 Well low volume black Polystyrene 
nontreated microplate (3677) 
Corning Life Sciences (Fisher Scientific, 
Schwerte, Germany) 
384 Well Polystyrene cell culture microplate, 
black (781091) Greiner Bio-One (Frickenhausen, Germany) 
384 Well Polystyrene cell culture microplate, 
white (781098) Greiner Bio-One (Frickenhausen, Germany) 
384 Well Small Volume HiBase Polystyrene 
Microplates, black (784076) Greiner Bio-One (Frickenhausen, Germany) 
384 Well Small Volume HiBase Polystyrene 
Microplates, clear (784101) Greiner Bio-One (Frickenhausen, Germany) 
Thermowell 96-well PCR plate Corning Life Sciences (Fisher Scientific, Schwerte, Germany) 
Nunclon cell culture plate Nunc (Wiesbaden, Germany) 
75 cm² flask TPP (Biochrom, Berlin, Germany) 
POLARstar Omega  BMG LABTECH (Offenburg, Germany) 
Steel beads (5 mm) QIAGEN (Hilden, Germany) 
TissueLyser QIAGEN (Hilden, Germany) 
ABI Prism 7900HT System Applied Biosystems (Darmstadt, Germany) 
Nanodrop ND-1000 Nanodrop (Fisher Scientific, Schwerte, Germany) 
Bioanalyzer RNA 6000 Pico Kit Agilent Technolgies (Böblingen, Germany) 
Bioanalyzer 2100  Agilent Technolgies (Böblingen, Germany) 
HumanHT-12 v3 Expression BeadChips Illumina (Eindhoven, The Netherlands) 
MouseWG-6 v2.0 Expression BeadChips Illumina (Eindhoven, The Netherlands) 
BeadStation 500  Illumina (Eindhoven, The Netherlands) 
Microvette lithium-heparin coated capillary 
tubes (CB300) Sarstedt (Nürnbrecht, Germany) 
Hemocue B-Glucose analyser  Hemocue (Großostheim, Germany) 
NuPAGE 4-12% Bis-Tris Gel Invitrogen (Karlsruhe, Germany) 
Hybond ECL nitrocellulose membrane GE Healthcare (München, Germany) 
LAS-1000 camera system Fujifilm (Düsseldorf, Germany) 
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2.15.4 Software 
Software Provider 
GraphPad Prism 5 GraphPad Software (La Jolla, CA, USA) 
Primer-BLAST 




SDS 2.2 Applied Biosystems (Darmstadt, Germany) 
BeadStudio 3.1  Illumina (Eindhoven, The Netherlands) 
DAVID 2008  
National Institute of Allergy and Infectious 
Diseases (NIAID) (Frederick, MD, USA, 
http://david.abcc.ncifcrf.gov) 
Mayday 2.8  
Center for Bioinformatics Tuebingen (ZBIT) 
(University of Tuebingen, Tuebingen, 
Germany, http://www.zbit.uni-tuebingen.de/ 
pas/software.htm) 
MeV 4.3  Dana-Farber Cancer Institute (Boston, MA, USA, http://www.tm4.org/mev) 
Gene Set Enrichment Analysis (GSEA) Broad Institute (Cambridge, MA, USA, 
www.broadinstitute.org/cmap) 
Connectivity Map, build 02  Broad Institute (Cambridge, MA, USA, 
www.broadinstitute.org/gsea) 
Image Reader LAS-1000 Pro V2.61  Fujifilm (Düsseldorf, Germany) 
ImageQuant TL GE Healthcare (München, Germany) 
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3  Results 
3.1  From plant to tube: In vitro characterization of novel PPAR ligands 
3.1.1 Amorfrutins are a novel class of PPAR-binding natural products 
To identify novel natural products that could act as anti-diabetic PPARγ ligands, 
we initially screened a natural product library consisting of approximately 8,000 
pure compounds of herbal and microbial origin by using a mass spectrometry-
based binding assay. The screen revealed several potential new PPARγ ligands, 
including a family of isoprenoyl-substituted benzoic acid derivatives, the 
amorfrutins (Figures 7 and S1, and table S1). This natural product class was 
mainly isolated from the edible roots of licorice, Glycyrrhiza foetida, and the 
fruits of the related legume Amorpha fruticosa, from which the name of the 








Time-resolved fluorescence resonance energy transfer (TR-FRET) assays revealed 
further biophysical characteristics of identified PPARy ligands. In a competitive 
binding assay the affinity constants (Ki) for binding of the amorfrutins to the 
PPARγ-LBD ranged from low-nanomolar to low-micromolar range (table S1). 
For instance, amorfrutin NP-015142 strikingly bound to PPARγ with a Ki of 
19 nM, which is in the range of the anti-diabetic drug rosiglitazone (7 nM, table 
1). This is the first report of a natural product binding to PPARγ with such high 
affinity. Amorfrutins 1 to 4, which were used in subsequent experiments, showed 
 





















Figure 7. Structures of the four amorfrutins that were further analysed and corresponding 
lead structure. R1: Isoprenoyl residues; R2: H or Me; R3: H or isoprenoyl residues; R4: H, 
aliphatic or aromatic residues or a combination thereof. 
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Ki values of 236 nM, 287 nM, 352 nM and 278 nM, respectively (Figure 8A and 
















The amorfrutins also showed micromolar binding to PPARα and PPARβ/δ with 
selectivities ranging from 10-fold to 200-fold for PPARγ (Figures 8B, 8C and 
table S1). For instance, amorfrutin 3 is a very selective nanomolar PPARγ ligand, 
as its binding constants are 115 µM and 68 µM for PPARα and β/δ, respectively. 
In contrast, amorfrutin NP-015142 also has high affinity to PPARα and β/δ with 
binding constants of about 2 µM (table S1), indicating that NP-015142 is a pan 
PPAR agonist. In summary, dependent on the compound concentration, 
amorfrutins are potent PPARγ ligands with the potential to additionally activate 
PPARα and PPARβ/δ. This suggests that these natural products could contribute 
 






























































































Figure 8. Binding of compounds on the ligand binding domain (LBD) of (A) PPARγ, (B)
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to treatment of diabetes and related diseases such as dyslipidemia and 













To gain further insight into the interaction of amorfrutins with PPARγ, the 
structure of the complex of the PPARγ-ligand binding domain (LBD) and 
amorfrutin 1 was determined by X-ray crystallography in cooperation with Jens C. 
de Groot and Dr. Konrad Büssow (Division of Structural Biology, Helmholtz 
Centre for Infection Research, Braunschweig, Germany). Binding of full agonists 
such as rosiglitazone or pioglitazone is known to stabilize helix H12 of PPARγ 
(73). In contrast, the novel agonist amorfrutin 1 was bound between helix H3 and 
the β-sheet, thus stabilizing this region. The structure showed that amorfrutin 1 
was recognized by PPARγ in a similar way as the partial agonists nTZDpa and 
MRL-24, and also the intermediate agonist BVT.13 (209). Similar to these 
selective PPARγ modulators (SPPARγMs), amorfrutin 1 was bound by Ser342 
and Arg288 of the LBD via hydrogen bonds, especially to the carboxyl group of 
the amorfrutins. Disruption of these interactions by methylating the carboxyl 
Table 1. Affinity constants (Ki) and effective concentrations (EC50) of investigated 
compounds binding to PPARγ. Ki values were obtained by using a competitive TR-FRET 
assay, EC50 and efficacy values were determined from a reporter gene assay. Efficacy is 
the maximum activation relative to the rosiglitazone-induced activation of PPARγ. 
 
Ki EC50 Efficacy
Amorfrutin 1 236 nM 458 nM 39%
Amorfrutin 2 287 nM 1.2 µM 30%
Amorfrutin 3 352 nM 4.5 µM 22%
Amorfrutin 4 278 nM 979 nM 15%
Rosiglitazone 7 nM 2 nM 100%
Pioglitazone 584 nM n.d. n.d.
nTZDpa 29 nM n.d. n.d.
Telmisartan 1.7 µM n.d. n.d.
PPARγCompound
 
n.d., not determined. 
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group in amorfrutin 5 weakened the binding to PPARγ by a factor of 40 (Figure 
9). The structure also revealed that the ortho-phenyl and meta-isoprenoyl residues 
of amorfrutin 1 have extensive van der Waals contacts with the LBD, thus 
explaining the high binding affinity. The structure clearly described the 











3.1.2  Amorfrutins partially recruit transcriptional cofactors to PPARγ  
It is a well accepted model that binding of different ligands induce specific 
conformational changes in the LBD and AF2-domain of PPARs, and that this 
consequently leads to compound-specific interactions of the nuclear receptor with 
different sets of transcriptional cofactors, and further to different effects on gene 
expression (74, 75). In an in vitro cofactor recruitment assay amorfrutins and the 
other partial ligands nTZDpa (210) and telmisartan (211) only partially recruited 
the coactivators TRAP220/DRIP-2, PGC1α (PPARγ coactivator 1α), 
PRIP/RAP250 and CBP (CREB binding protein) relative to the full PPARγ 
agonists rosiglitazone and pioglitazone (Figure 10 and table S2). Compared to 
rosiglitazone, binding of amorfrutins led to reduced release of the transcriptional 
corepressor NCOR2 (nuclear receptor corepressor 2). The corresponding EC50 
values were in the nanomolar or low-micromolar range. Intriguingly, although the 
 





























Figure 9. Effect of esterification of amorfrutins acidic head group. (A) Structure of 
amorfrutin 5 and its methylester (ME) derivative. (B) Binding on PPARγ in a competitive 
TR-FRET assay. Esterification increased the binding constant from 590nM to 23µM. Data 
are expressed as mean ± s.d. (n=3). 
A B 
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binding affinities are similar for all four amorfrutins, they exhibited distinct 
cofactor recruitment profiles, e.g. with an EC50 range from 0.1 to 77 µM with 
corresponding efficacy ranging from 6 to 24% in case of CBP recruitment. Thus, 
small variations in the ligand structure more likely affect the cofactor recruitment 
profile than the binding affinity. These experiments indicate that amorfrutins are 






























































































































































Figure 10. Recruitment of various cofactor peptides to PPARγ-LBD that is bound to 
different compounds. Peptides are derived from coactivators (A) TRAP220/DRIP-2, (B)
PGC1α, (C) PRIP/RAP250, (D) CBP-1, or (E) corepressor NCOR2. Data are expressed as 
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3.1.3 Amorfrutins partially activate PPARγ in cell culture  
Cell-based transactivation of PPARγ was carried out using a reporter gene assay, 
revealing that amorfrutins are partial PPARγ agonists with activation values of 15 
to 39 % compared to 
rosiglitazone. The EC50 values 
were 458 nM, 1.2 µM, 4.5 µM 
and 979 nM for amorfrutin 1, 2, 
3 and 4, respectively (Figure 11 
and table 1). Since the detection 
of only slightly activating ligands 
is hindered by low signal 
intensities, we additionally 
measured PPARγ activation in 
presence of non-saturating 
concentrations of rosiglitazone (Figure S2). This experimental modification 
verified the partial PPARγ agonism of the amorfrutins.  
 
3.2 From tube to bench: Effects of amorfrutins in target cells 
3.2.1  Amorfrutins induce expression of PPARγ targets in adipocytes 
Nuclear receptors such as PPARγ regulate the expression of hundreds or 
thousands of genes involved in metabolism. Subsequent to the in vitro binding 
and transactivation experiments, the amorfrutins were investigated in target cells 
of metabolic diseases. Therefor, differentiated 3T3-L1 mouse adipocytes were 
incubated for 24 h with 20 µM of each amorfrutin and gene expression was 
analyzed by quantitative real-time PCR (qPCR). The amorfrutins significantly 
upregulated classical PPARγ target genes such as the fatty acid binding protein 4 
(Fabp4), the glucose transporter 4 (glut4, Slc2a4) and the liver x receptor alpha 
(lxra, Nr1h3). Consistent with the concept of partial agonism, the upregulation of 



























Figure 11. Cellular activation of PPARγ 
determined in a reporter gene assay. Data are 
expressed as mean ± s.d. (n=3). 
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gene expression was reduced for amorfrutins compared to the full agonist 














3.2.2  PPARγ knockdown confirms selectivity of amorfrutins  
To verify the supposed mechanism of gene expression modulation via PPARγ 
activation, specificity of compound effects was investigated in siRNA-mediated 
PPARγ-knockdown in human primary adipocytes. A protocol for chemically 
induced siRNA-transfection of primary adipocytes was established, which was not 
reported so far. The PPARγ knockdown efficiency reached 82% on transcript 
level compared to unspecific negative siRNA (Figure 13A). In presence of 
negative siRNA amorfrutin 1 and 2 activated expression of HSD11B1, LPL, 
CD36 and PLTP. Knockdown of PPARγ significantly reduced or abolished the 
amorfrutin-induced gene expression modulation, verifying the specificity of 



































































































Figure 12. Gene expression analysis of compound-treated 3T3-L1 adipocytes determined by 
qPCR. Data are expressed as mean ± s.e.m. (n=4). *, P≤0.05 vs. vehicle. 













3.2.3  Amorfrutins regulate metabolism and immunity in adipocytes  
Genome-wide gene expression analyses in primary human adipocytes were 
performed on Illumina Beadchip arrays. Real-time qPCR was used to validate the 
array experiments. Therefor, four genes were randomly chosen from the array data 
and correlated to qPCR-derived expression values. The bead array data were in 
correlation with the qPCR data, with Pearson correlation coefficients of 0.79, 
0.78, 0.57 and 0.51 for ADIPOQ, NR1H3, HSD11B1 and FABP4, respectively 
(Figure S3). This led to an average Pearson correlation coefficient of 0.66 for all 
genes tested by qPCR, indicating an adequate congruence between both 
techniques. 
Whole-genome gene expression analyses of human primary adipocytes treated 
with amorfrutins, the full PPARγ agonists rosiglitazone and pioglitazone, the 
selective PPARγ modulators nTZDpa (210) and telmisartan (211), or vehicle only, 
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Figure 13. Effects of RNA interference with PPARγ-siRNA (A) on PPARγ gene expression 
and (B) on amorfrutin-mediated effects in human primary adipocytes. Data are expressed as 
mean ± s.e.m. (n=4). #, P≤0.05 vs. negative siRNA. 
A B 
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expression of 309 and 177 genes, respectively, whereas amorfrutin 1 and 












The most highly significant up- and down-regulated genes after treatment with 
amorfrutin 1 and 2 are shown in table 2. Classical genes involved in lipid 
metabolism and insulin signalling were regulated upon treatment with 
amorfrutins. For instance, amorfrutin 1 induced the expression of 
phosphodiesterase 3B (PDE3B), which was shown to be down-regulated in the 
adipose tissue of rodent models of type 2 diabetes (212, 213). Furthermore, 
amorfrutin 1 increased the gene expressions of adiponectin (ADIPOQ) and 
lipoprotein lipase (LPL). In previous studies adiponectin was found to reduce 
body adiposity by affecting the mRNA expression of uncoupling proteins (UCPs) 
in adipose tissue and skeletal muscle (214). The lipoprotein lipase catalyzes the 
hydrolysis of triglycerides of circulating lipoproteins and was thought to mediate 
the hypotriglyceridemic effects of fibrates and thiazolidinediones (215). 
Amorfrutin 2 up-regulated genes such as the hormone-sensitive lipase (LIPE), the 

























Figure 14. Venn diagrams of differentially expressed genes after treatment of human 
adipocytes with different compounds. (A) Comparison of amorfrutins with rosiglitazone. 
(B) Comparison of amorfrutins with nTZDpa. Numbers in circles indicate up- and down-
regulated genes, numbers in parentheses represent a total of regulated genes for that 
compound. 
A B 
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Hierarchical clustering of the compounds and k-means clustering of differentially 
expressed genes were carried out to systematically sort expression data. Then, 
gene clusters were checked for functional annotation enrichment using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(Figure 15), resulting in six clusters of differentially regulated genes. The first 
cluster contained genes that were up-regulated by all PPARγ ligands and 
comprised genes involved in PPAR signalling including fatty acid metabolism 
(e.g. adiponectin), carbohydrate metabolism (e.g. pyruvate dehydrogenase kinase 
4) and lipid synthesis (e.g. aquaporin 7). Almost all genes in the second cluster 
Table 2. The 12 most highly significant up- and down-regulated genes after treatment of 
human adipocytes with amorfrutin 1 and 2. Fold change means gene expression relative to 
vehicle-treated cells. Data are expressed as mean (n=4). 
 
Gene Fold Change Gene Fold Change
HLA-DMA 2.5 PPP1R1A 4.9
AP3B2 2.4 AP3B2 2.7
SLC19A3 2.3 MLSTD1 2.5
PDE3B 2.1 FABP5 2.4
KIAA1881 2.1 SHROOM4 2.4
MRAP 2.0 HLA-DMA 2.3
CSAD 2.0 UCP2 2.3
MLSTD1 2.0 LIPE 2.2
AOC3 2.0 CSAD 2.2
OSGIN1 1.9 PLIN4 2.2
ADIPOQ 1.8 MTHFD1 2.2
LPL 1.8 MESP1 2.1
PIK3IP1 0.7 PDE1A 0.7
SULF1 0.7 SOD2 0.7
C20ORF111 0.7 MXRA5 0.7
C5ORF23 0.7 OSAP 0.7
C20ORF82 0.7 KLF2 0.7
OMD 0.7 C11ORF2 0.7
TNFSF10 0.7 PENK 0.6
FLRT2 0.6 CCBP2 0.6
CABC1 0.6 PPP1R3C 0.6
PPP1R3C 0.5 SERPINA5 0.6
SERPINA5 0.5 MLPH 0.6
CYP4F22 0.3 CYP4F22 0.5
Amorfrutin 1 Amorfrutin 2
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were activated only by the TZD pioglitazone and were predominantly involved in 
protein biosynthesis and carboxylic and amino acid transport. Genes in the third 
cluster had functions in lipid and fatty acid metabolism and were mainly up-
regulated by rosiglitazone. These genes were only slightly activated by 
amorfrutins and nTZDpa and encompassed the fatty acid binding protein 4 
(FABP4) and the cortisone-regenerating enzyme hydroxysteroid 11-beta 
dehydrogenase 1 (HSD11B1) that is correlated to visceral adiposity (216). The 4th 
cluster contained genes with the most diverse regulation among the PPARγ 
ligands tested and comprised genes strongly involved in the secretion of 
molecules, which verified the function of adipose tissue as an endocrine organ 
(31). Additionally, genes of the 4th cluster play important roles in the metabolism 
of fatty acids, e.g. the gene lipin 1 is mainly involved in the oxidation of free fatty 
acids, which is controlled by the PPARα isotype (217). In this study lipin 1 was 
only upregulated by the dual PPARα/γ ligand telmisartan (218) and amorfrutin 4 
that could be shown to bind PPARα as well (Figure 8 and table 1). Genes in the 
5th cluster were differentially down-regulated by these compounds and had 
functions not only in the secretion but also in the inhibition of proteases and 
developmental processes. Remarkably, the 6th cluster contained genes that were 
mainly down-regulated by the full agonists rosiglitazone and pioglitazone. These 
genes are linked to ion homeostasis and inflammatory processes besides secretion 
and protease inhibition. Recently, it was reported that TZDs can cause edema due 
to an increased plasma volume (219). This could be a result of altered ion 
homeostasis, which was an enriched term in the 6th gene cluster. For instance, 
expression of the sodium exchanger SLC9A9 was specifically down-regulated 
























In conclusion, the full and partial synthetic PPARγ agonists as well as the 
amorfrutins exhibited differential effects on gene expression in human adipocytes. 
The hierarchical clustering of the small molecules revealed similarity between the 
amorfrutin expression profiles. Nevertheless, gene expression profiles of the 
amorfrutins were partially distinct, indicating that small changes in ligand 






























































protein biosynthesis, carboxylic and amino acid 
transport, response to oxidative stress, 
cell proliferation
lipid metabolism, monocarboxylic acid metabolic 
process, fatty acid oxidation
secretion, metabolism of amino groups, fatty acid 
and isoprenoid metabolism, carboxylic & amino 
acid metabolism
secretion, protease inhibitor, developmental process
secretion, cell adhesion, protease inhibitor, 






Figure 15. Heatmap of differentially expressed genes after treatment of human adipocytes 
with different compounds. Illumina BeadChip data were filtered for significance and 
clustered with the k-means clustering algorithm. Enrichmend of clustered genes were 
annotated using DAVID 2008. Genes are presented as either up-regulated (red) or down-
regulated (blue). 
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To circumvent the low sensitivity of singular gene enrichment analyses, Gene Set 
Enrichment Analysis (GSEA) was performed on the adipocytes expression data. 
The gene sets comprised canonical pathways and data from chemical and genetic 
perturbation experiments. Gene sets that were significantly changed (FDR≤0.25) 
by at least one compound are presented in Figure S4. Gene sets were displayed as 
either up-regulated (red) or down-regulated (blue) in the compound expression 
profiles. In contrast to the list of single genes (Figure 15), the compounds showed 
an overall correlation in the enrichment of gene sets, indicating a common 
mechanism of action, namely PPARγ agonism.  
As expected for PPARγ agonists, the most enriched pathways for amorfrutin 1 
and 2 include PPAR signalling, cholesterol biosynthesis, fatty acid elongation and 




































Subsequently, we filtered out gene sets from the collection that were linked to 
either fatty acid metabolism or inflammation. As depicted in Figure 17A, fatty 
acid metabolism-related gene sets were significantly enriched in the gene 
expression data of all PPARγ agonists described in this study. The degree of 
enrichment, as described as normalized enrichment score (NES), was similar for 
























PPAR signaling pathway (# ‚ x, $)
Biosynthesis of steroids (KEGG) (# ‚ x, $)
Biosynthesis of steroids (GenMAPP) (# ‚ x, $)
Cholesterol biosynthesis (# ‚ x, $)
Mitochondrial fatty acid betaoxidation (# ‚ x, $)
Butanoate metabolism (KEGG) (# ‚ x, $)
Glycerophospholipid metabolism (# ‚ x, $)
Fatty acid elongation in mitochondria (# ‚ x, $)
Type I diabetes mellitus (#, $)
Butanoate metabolism (GenMAPP) (# ‚ x, $)
Olfactory transduction (#)
Toll-like receptor signalling pathway (#, x)





CCR5 pathway (#, $)
Complement and coagulation cascades (#‚ x, $)







Figure 16. Enriched pathways after treatment of human primary adipocytes using GSEA. 
Ten most highly significant pathways for amorfrutin 1 and corresponding normalized 
enrichment scores (NES) are shown. #, x, $, P≤0.05 for amorfrutin 1, amorfrutin 2 or 
rosiglitazone. 
Results - 68  
pro-inflammatory gene sets were significantly under-represented in the expression 
profiles of the investigated PPARγ ligands (Figure 17B and table S3). This 
underscores the role of PPARγ in the inhibition of inflammatory responses (220, 
221), and indicates anti-inflammatory properties of the amorfrutins, which should 


















































































Figure 17. Effects on gene expression related to fatty acid metabolism (A) and 
inflammatory pathways (B). Normalized enrichment scores for each gene set were 
calculated with compound-specific expression profiles by GSEA. Gene sets were filtered 
with FDR≤0.25 for at least one compound. For full description of corresponding gene set 
names see Supplementary table S3. 
A 
B 
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The Connectivity Map tool (204) can be used to connect small molecules sharing 
a mechanism of action. Gene expression data were validated by comparing with 
implemented data obtained from other research groups. Connection of the 
rosiglitazone profile in human adipocytes revealed similarities to other 
rosiglitazone data obtained in PC3 or HL60 cells. Four different rosiglitazone 
experiments appeared under the most highly significant 13 connections to small 
molecules, including the most significant experiment (table S4). Additional seven 
connections revealed similarity to the other TZDs pioglitazone and troglitazone 
and the endogenous PPARγ agonist 15-delta prostaglandin J2. This indicates that 
in spite of comparing to other human cell lines as adipocytes, our rosiglitazone 
data as an example of the signatures described in this study were in accordance 
with experiments done in other labs. 
Furthermore, applying the Connectivity Map tool to our amorfrutin 1 gene 
expression profile unravelled the broad mechanism of action. A strong 
anticorrelation to the phosphoinositide 3-kinase (PI3K) inhibitor LY-294002 
(p<10-5, table 3) could be observed. Activation of PI3K is an early event in 
insulin signalling and it has been shown that insulin sensitizers as TZDs increase 
PI3K activity in adipocytes (222). Besides LY-294002, the mammalian target of 
rapamycin (mTOR) inhibitor sirolimus was also negatively connected to the 
amorfrutin 1 profile (p<10-5). mTOR acting downstream of PI3K was recently 
shown to counteract PPARγ effects (223). Experiments with the insulin sensitizer 
troglitazone revealed positive connection with the amorfrutin 1 gene expression 
signature (p<10-3). Enhancing insulin sensitivity could also be verified by 
collapsing the Connectivity Map implemented small molecule data to Anatomical 
Therapeutic Chemical (ATC) classification (table 3). The code A10BG (blood 
glucose lowering drugs, thiazolidinediones) includes different PPARγ ligands for 
the treatment of diabetes and showed the most significant connection to the 
amorfrutin data (p<10-5). These results again revealed that amorfrutins are acting 
through PPARγ modulation and had high potential for application as insulin 
sensitizers. 
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3.2.4  Amorfrutins are selective PPARγ modulators (SPPARγMs) 
Since treatment with approved, strongly activating PPARγ agonists is associated 
with unwanted side effects, ligands with selective modulation profiles are required 
(74, 104, 133, 136). Hypergeometrical testing was applied to the lists of regulated 
genes to further compare the expression signatures of amorfrutins with those of 
full and partial PPARγ agonists. This analysis revealed an overlap with an 
enrichment factor of 26 for amorfrutin 1/rosiglitazone and an overlap with an 
enrichment factor of 67 for amorfrutin 1/nTZDpa relative to expectation by 
chance. Consequently, a first assessment of the expression data showed that the 
gene signatures of the natural products were more closely related to those of 
SPPARγMs than to the profiles of full PPARγ agonists. 
To include the intensities of gene expression changes in gene signature 
comparison, principal component analyses (PCA) were performed. Gene 
expression profiles of amorfrutin 1 and 2 correlated in the first two principal 
components (~70% of the data variability) more efficiently with the SPPARγMs 
nTZDpa and telmisartan than with the full PPARγ agonists (Figure 18). The 
results were similar with the other amorfrutins described in this study (data not 
shown).  
Table 3. Connectivity of the amorfrutin 1 gene expression profile in human adipocytes 
with other small molecules using the Connectivity Map. (Top) The three most significant 
connections with small molecules from different experiments and cell lines. (Bottom) Best 
connection with small molecules sharing the same Anatomical Therapeutic Chemical 
(ATC) classification.  
 
 
 rank cmap name mean n enrichment p specificity percent non-null
1 LY-294002 -0.538 61 -0.538 0.00000 0.0245 85
2 sirolimus -0.505 44 -0.447 0.00000 0.1507 79
3 troglitazone 0.269 16 0.515 0.00018 0.0000 50
rank atc code mean n enrichment p specificity percent non-null














Since the PCA included only ca. 2/3 of the gene expression changes, a gene 
distance matrix (GDM) analysis was additionally performed to compare the gene 
expression profiles (Figure 19). As expected, the amorfrutin gene expression 
profiles showed similarities among each other, and were closer to the SPPARγMs 
than to the TZDs. These gene expression analyses clearly showed that amorfrutins 

























































































Figure 19. Gene distance matrix of gene expression profiles in human adipocytes. Squares 
show the distance of two compounds in Euclidean space, ranging from exactly the same 













































Figure 18. Principal Component Analysis (PCA) of differentially expressed genes after 
treatment with different PPARγ ligands, including the full agonists rosiglitazone and 
pioglitazone and the selective PPARγ modulators nTZDpa and telmisartan. The first two 
principal components (PC1, PC2) were plotted on the axis. Number in parentheses represent 
the variability of that principal component. The plots show 70% of the data variability (A)
for amorfrutin 1 and 71% of the data variability (B) for amorfrutin 2.  
A B 
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3.2.5  Amorfrutins show promising ADMET properties  
Successful treatment of mice requires good ADMET (Absorption, Distribution, 
Metabolism, Excretion, Toxicity) parameters. To exclude cytotoxic effects of the 
amorfrutins the WST-1 assay was applied in HepG2 cells with different 
concentrations of amorfrutins. The amorfrutins revealed no effects on cell 
viability up to 50 µM compound concentration (Figure S5). Similar results were 
observed in other cell lines including adipocytes (data not shown). 
Analyses in conjunction with the Lead Discovery Center (Dortmund, Germany) 
revealed that, first, the amorfrutins had a highly aqueous solubility, second, the 
amorfrutins showed good absorption and permeability in the PAMPA (parallel 
artificial membrane permeability assay) as well as in the Caco-2 cell model, and 
third, in vitro metabolic stability assays in liver microsomes indicated 
vulnerability for oxidation and glucuronidation under metabolic phase I and II 
conditions, respectively. Non-metabolized amorfrutin 1 was identified as the main 
form in murine plasma (66% abundance). Glucuronidated (25%) and oxidized 
(8%) metabolites were further detected. In summary, the amorfrutins had 
promising ADMET properties that accounted for further in vivo studies. 
 
3.3 From bench to mouse: Animal studies  
The anti-diabetic and anti-obesity potential of the amorfrutin class were validated 
by applying three different study designs: first, the prevention of diet-induced 
insulin resistance and obesity in C57BL/6 mice (37 mg/kg/d amorfrutin over 15 
weeks), second, the therapy of distinctive insulin resistance and obesity in diet-
induced-obesity (DIO) mice (100 mg/kg/d amorfrutin over 3 weeks), and third, 
the therapy of type 2 diabetes in leptin receptor deficient db/db mice (100 mg/kg/d 
amorfrutin over 3 weeks). Amorfrutin 1 was incorporated into the diet. The 
PPARy agonist rosiglitazone (4 mg/kg/d), which is widely used for anti-diabetic 
treatment, was used as positive control. The same diet without compound 
incorporation was used as vehicle control. 
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3.3.1  Amorfrutin 1 has a safe profile on liver toxicity in mice  
Liver toxicity indicating plasma alanine transaminase (ALT) assays showed 
significantly reduced ALT levels in high fat diet (HFD)-fed mice treated with 
amorfrutin 1 compared to HFD mice treated with vehicle control or rosiglitazone 
(Figure S6). Similarly, microarray-based gene expression analysis revealed no 
toxicity after amorfrutin treatment (table S5). 
 
3.3.2 Amorfrutin 1 reduces insulin resistance, dyslipidemia and obesity         
in DIO mice  
High-fat diet feeding of mice results in diet-induced obesity (DIO) and insulin 
resistance. Therefor, lean C57BL/6 mice were firstly fed for 12 weeks with high-
fat diet (HFD). Subsequently, the mice were treated for 23 days with 100 mg/kg/d 
synthetic amorfrutin 1, 4 mg/kg/d rosiglitazone or vehicle control. Amorfrutin 1 
considerably reduced plasma glucose, insulin, triglyceride and free fatty acid 
levels under fasted and fed conditions (Figure 20 and tables S6 to S7). Both 
amorfrutin 1 and rosiglitazone showed equal reduction of insulin resistance as 
assessed by homeostatic modelling (Figure 20E).  
 



















Amorfrutin 1 considerably enhanced glucose tolerance (19% decrease in 
glucose area under the curve (AUC), 42% decrease in insulin AUC vs. vehicle) 
and insulin sensitivity (14% increase in glucose inverse area under the 
curve (AUCi) vs. vehicle) during oral glucose tolerance tests (OGTT, 
Figure 21A) and intraperitoneal insulin sensitivity tests (IPIST, Figure 21B). In 
summary, amorfrutin 1 treatment of obese mice showed anti-diabetic efficacy 



















































































































Figure 20. Effects of treatment over 17 days on plasma parameters in fasted DIO mice. (A)
Insulin, (B) glucose, (C) triglycerides, (D) free fatty acids. (E) Insulin resistance was 
determined by homeostatic model assessment (HOMA). Data are expressed as mean ± s.e.m. 
(n=13). Veh, vehicle; Ros, rosiglitazone; A1, amorfrutin 1. *, P≤0.05 vs. vehicle. 
A B C 
E D 

















Strikingly, amorfrutin 1 clearly reduced the body weight in DIO mice by ~10%. 
Paradoxically, weight reduction was accompanied by an increase in food intake 
(Figure 22). In contrast, rosiglitazone treatment led to a raise in feeding without 
any weight change in this study. Increase of appetite has already been reported for 
several PPARγ ligands and is thought to attribute to the TZD-induced weight gain 
observed in many studies (224). However, amorfrutins probably regulates whole-
body energy balance different to rosiglitazone. Importantly, weight loss upon 
amorfrutin treatment was not due to toxic effects that had been excluded by 
assaying plasma ALT concentrations and by liver gene expression analyses 
(Figure S6 and table S5). 
 






































































































































































































































Figure 21. Effects on insulin resistance and glucose intolerance in DIO mice (n=13). (A)
Glucose and insulin concentrations during oral glucose tolerance test (OGTT) treated with 
indicated compounds. Inlet, area under the curve (AUC). (B) Glucose level during 
intraperitoneal insulin sensitivity test (IPIST). Inlet, inverse area under the curve (AUCi). 
Data are expressed as mean ± s.e.m. *, P≤0.05 vs. vehicle. 
B 
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Figure 22. Effect of treatment on body weight (A) and food intake (B) in DIO mice 
(n=13). Data are expressed as mean ± s.e.m. *, P≤0.05 vs. vehicle. 
A B 
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3.3.3 Amorfrutin 1 prevents development of insulin resistance and 
dyslipidemia in HFD-fed mice 
We further investigated the potential of amorfrutins to prevent early development 
of insulin resistance. C57BL/6 mice were fed either a low-fat diet (LFD) or a 
high-fat diet (HFD) in absence or presence of rosiglitazone (HFD+R, 4 mg/kg/d) 
or low-dose amorfrutin 1 (HFD+A1, 37 mg/kg/d), respectively, for 15 weeks. 
Amorfrutin 1 reduced the HFD-induced weight gain by 22% without reducing 
food intake (Figure S7), and significantly improved glucose tolerance (22% 
decrease in insulin AUC) and insulin sensitivity (21% increase in glucose AUCi) 













Additionally, amorfrutin 1 substantially diminished the rise of plasma 
triglycerides, free fatty acids, insulin and glucose (tables S8 to S9). Besides, 
treatment with amorfrutin 1 led to increased liver glycogen content, which is a 
characteristic for anti-diabetic agents (Figure 24A) (225). Furthermore, 
amorfrutin 1 significantly reduced the increase of plasma concentrations of the 





































































































































Figure 23. Effects of low-fat diet (LFD) or high-fat diet (HFD) without or with rosiglitazone 
(HFD+R) or amorfrutin 1 (HFD+A1) on glucose tolerance and insulin sensitivity in 
C57BL/6 mice (n=8-12). (A) Insulin concentrations during oral glucose tolerance test 
(OGTT) after 10 weeks of dosing. Inlet, area under the curve (AUC). (B) Glucose levels 
during intraperitoneal insulin sensitivity test (IPIST) after 13 weeks of dosing. Inlet, inverse 
area under the curve (AUCi). Data are expressed as mean ± s.e.m. *, P≤0.05 vs. HFD. 
A B
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adipose derived hormone leptin (Figure 24B), which could have in part 
contributed to the improved metabolic profile observed. In summary, amorfrutin 1 













3.3.4 Amorfrutin 1 ameliorates insulin sensitivity and dyslipidemia               
in db/db mice  
To figure out potential contributions of the leptin hormone and to validate the 
anti-diabetic effects in a model of severe type 2 diabetes, we also treated leptin 
receptor-deficient db/db mice with amorfrutin 1 (100 mg/kg/d), rosiglitazone (4 
mg/kg/d) or vehicle for 3 weeks. In this model, rosiglitazone strongly increased 
the body weight by ~30% within 3 weeks, whereas amorfrutin 1 treatment had no 
significant effects on mouse body weight (Figure 25). Notably, in db/db mice 
amorfrutin 1 reduced plasma insulin concentrations more strongly than 
rosiglitazone (36% vs. 19% decrease after 24 days) (Figure 26). Amorfrutin 1 
treatment decreased plasma concentrations of glucose, triglycerides and free fatty 










































































Figure 24. Effect of treatment over 15 weeks on (A) liver glycogen concentration (n=12) 
and (B) plasma leptin (n=9-12) in C57BL/6 mice. Data are expressed as mean ± s.e.m. 
*, P≤0.05 vs. HFD. 
A B
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amorfrutin 1 considerably prevented and ameliorated type 2 diabetes and 













3.3.5 Amorfrutin 1 inhibits HFD-induced PPARγ phosphorylation 
Recently, it was reported that the development of insulin resistance is associated 
with phosphorylation of PPARγ-Ser273, and that this phosphorylation can be 
inhibited by PPARγ ligands independently from PPARγ activation (147). 
Therefore, inhibition of Ser273-phosphorylation was proposed as a new strategy 
to increase specifically insulin sensitivity without activating the full range of 
PPARγ targets (see 1.3.1.3.). Indeed, treatment of HFD-fed mice with 
rosiglitazone inhibited the phosphorylation of PPARγ-Ser273 in vWAT. 
Moreover, treatment with the SPPARγM amorfrutin 1 led to similar reduction of 
phosphorylation (Figure 27A). Furthermore, decrease of PPARγ phosphorylation 






































Figure 26. Effect of treatment on fasting 
plasma insulin level of diabetic db/db 
mice (n=7-12). Data are expressed as 
mean ± s.e.m. *, P≤0.05 vs. vehicle. 




































Figure 25. Effect of treatment over 3 
weeks on body weight in db/db mice 
(n=13). Data are expressed as mean ± 
s.e.m. *, P≤0.05 vs. vehicle. 


















This experiment verifies the recent hypothesis that blocking of PPARγ 
phosphorylation is independent from transcriptional agonism, and that this 
inhibition but not PPARγ activity is linked to improved insulin sensitivity. 
Choi et al. (147) further reported that inhibition of PPARγ phosphorylation 
resulted in specific transcription of 17 target genes. Indeed, 14 of them were 
significantly regulated upon treatment of mice amorfrutin 1 (Figure 28), 






Figure 27. Correlation between inhibition of PPARy phosphorylation and insulin 
sensitivity after treatment. (A) Phosphorylation of Ser273 PPARy in visceral white adipose 
tissue (vWAT) of HFD-fed mice treated with rosiglitazone, amorfrutin 1 or vehicle for 15 
weeks. The rate of PPARy phosphorylation was normalized to total PPARy protein using 
densitometric analyses. Data are expressed as mean ± s.e.m. (n=11-12). *, P≤0.05 vs. 
vehicle. (B) Correlation between insulin sensitivity measured in the insulin sensitivity test 
(expressed as AUCi) and PPARy phosphorylation. Pearson correlation coefficient and 
corresponding P value (two-tailed) are shown (n=35). 
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B














3.3.6 Amorfrutin 1 reduces detrimental deposit of lipids in various tissues  
Accumulation of triglycerides and free fatty acids in non-adipose tissues 
contributes to lipotoxicity and tissue damage (188, 226). In addition to 
improvement of plasma lipid levels, amorfrutin 1 reduced the concentration of 
detrimental free fatty acids in the heart of db/db mice by 50% (Figure 29A), 
whereas rosiglitazone only had minor effects. Rosiglitazone further increased the 
triglyceride concentration in liver and pancreas, whereas amorfrutin 1 did not 
show lipogenic effects (Figure 29B). In stark contrast to rosiglitazone, 
amorfrutin 1 reduced HFD-induced accumulation of liver triglycerides by ~50% 










































































































Figure 28. Expression of genes regulated by inhibition of PPARγ-Ser273 phosphorylation 
in white adipose tissue of DIO mice according to ref. (147). Gene expression of vehicle-
treated  mice is set to 1. Data are expressed as mean ± s.e.m. *, P≤0.05 vs. vehicle.  





















































































































































Figure 29. Effects of PPARγ modulators on lipid deposit in different mouse models of type 
2 diabetes. (A) Effect of treatment over 3 weeks on free fatty acids in the heart of db/db mice 
(n=13). (B) Effect of treatment over 3 weeks on liver and pancreas triglycerides of db/db 
mice (n=10-13). (C) Effect of treatment over 15 weeks on liver histology (left) and liver 
triglycerides (right) of C57BL/6 mice (n=6-7). Data are expressed as mean ± s.e.m. 
*, P≤0.05 vs. vehicle or HFD only, respectively. 
A B
C
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3.3.7 Amorfrutin 1 has protective effects on pancreas  
A hallmark of the progressive development of diabetes is pancreatic tissue 
exhaustion. This is accompanied by decreased capacity of the β-cells to produce 
insulin, and by elevated plasma levels of the insulin precursor proinsulin (227). 
Possibly due to improved insulin sensitivity, amorfrutin 1 also appeared to prevent 
deterioration of pancreatic function in all mice models tested, as pancreatic insulin 


























































Figure 30. Effect of treatment on pancreas integrity. (A) Pancreatic insulin content in DIO 
mice (n=13) or db/db mice (n=7) after treatment over 3 weeks. (B) Plasma proinsulin levels 
in C57BL/6 mice (n=10-12) after treatment over 15 weeks. Data are expressed as mean ± 
s.e.m. *, P≤0.05 vs. vehicle or HFD only, respectively. 
A B
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3.3.8 Amorfrutin 1 promotes expression of genes of lipid breakdown 
Gene expression analyses in liver elucidated the underlying mechanism of 
reduced liver steatosis upon amorfrutin treatment. Rosiglitazone excessively 
activated expression of the fatty acid binding protein 4 (Fabp4) up to 55-fold, 
accounting for increased adipogenesis in the mouse liver (228). In contrast, 
amorfrutin 1 did not increase liver Fabp4 expression at all. Instead, amorfrutin 1 
induced the expression of genes responsible for fatty acid oxidation such as 
PPARγ coactivator 1α (Pgc1α), acyl-Coenzyme A oxidase 1 (Acox1) and 
carnitine palmitoyltransferases 1a and 2 (Cpt1a and Cpt2), which could contribute 













Recently, it was reported that accumulation of triglycerides in liver is causally 
linked to decreased expression of transducin beta-like (TBL) 1 (229), a 
transcriptional cofactor of PPARα, which is the master regulator of fatty acid 
oxidation. Consistently, TBL1 expression negatively correlated with liver 



















































Figure 31. Regulation of liver gene expression after feeding with low fat diet (LFD) and 
high fat diet (HFD) without or with rosiglitazone (HFD+R) or amorfrutin 1 (HFD+A1) over 
15 weeks in C57BL/6 mice (n=12). Expression of classical PPAR target genes was analyzed 
by qPCR. Gene expression of HFD-fed mice is set to 1. Data are expressed as mean ± s.e.m. 
*, P≤0.05 vs. HFD only. 
Results - 85  
steatosis (Figure 32A), and HFD feeding of mice led to a significant reduction in 
TBL1 expression compared to LFD-fed animals (Figure 32B). Strikingly, 
treatment with amorfrutin 1, but not rosiglitazone, completely inhibited the 














3.3.9 Amorfrutin 1 reduces HFD-induced inflammation and          
macrophage invasion  
Obesity is a chronic low-grade inflammation that is characterized by the 
expression of inflammatory mediators and macrophage recruitment to different 
tissues (17). In liver amorfrutin 1 reduced the transcript concentrations of the 
interleukins Il6 and Il1b, Lgals3, Ptgs2 and Ccl2 (MCP-1) (Figure 33A). Besides, 
amorfrutin 1 but not rosiglitazone decreased HFD-derived macrophage 
accumulation in liver as determined by expression of macrophage-specific 




Figure 32. Gene expression of cofactor Tbl1 in murine liver. (A) Pearson correlation 
coefficient and P value (one-tailed) shown for normalized gene expression of cofactor Tbl1 
versus triglyceride content in C57BL/6 liver samples (n=18). (B)  Change in gene 
expression after feeding of low-fat diet (LFD) or high-fat diet (HFD) without or with 
rosiglitazone (HFD+R) or amorfrutin 1 (HFD+A1) over 15 weeks in C57BL/6 mice 
(n=12). Data are expressed as mean ± s.e.m. *, P≤0.05 vs. LFD; #, P≤0.05 vs. HFD. 
A B 
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markers in amorfrutin 1-treated mice was comparable to that of lean LFD-fed 













Accordingly, tumor necrosis factor α (TNFα) protein concentrations were lowered 
in liver (Figure 34). The 
anti-inflammatory effects of 
amorfrutin 1 were also 
verified by gene expression 
analyses in viscerale white 
adipose tissue (vWAT) 
(Figure S8). Consequently, 
amorfrutin treatment also led 
to reduction of obesity-






Figure 34. Effect of treatment on TNFα protein 
concentrations in liver of C57BL/6 mice (n=6). Data 
are expressed as mean ± s.e.m. *, P≤0.05 vs. HFD. 
 


























































































































Figure 33. Regulation of liver gene expression after feeding with low-fat diet (LFD) or high-
fat diet (HFD) without or with rosiglitazone (HFD+R) or amorfrutin 1 (HFD+A1) over 15 
weeks in C57BL/6 mice (n=12). Expression of genes involved in inflammatory processes 
(A) and presence of macrophage-specific markers (B) were analyzed by qPCR. Gene 
expression of HFD-fed mice is set to 1. Data are expressed as mean ± s.e.m. *, P≤0.05 vs. 
HFD. 
A B
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4 Discussion 
The studies presented here introduces the amorfrutins, a novel natural product 
class of selective PPAR modulators, for effectively preventing and treating type 2 
diabetes and the metabolic syndrome with minimized side effects. 
 
4.1  The amorfrutin structure 
The core structure of the amorfrutins consists of a simple 2-hydroxy benzoic acid 
with diverse isoprenyl and phenyl moieties (Figure 7). In a competitive TR-
FRET-based binding assay binding affinity constants for these natural products 
could be determined. Affinity constants were in the high nanomolar range for 
PPARγ and in the medium to high micromolar range for PPARα and PPARβ/δ 
(table S1). The crystal structure of amorfrutin 1 in complex with the PPARγ-LBD 
in combination with the systematic synthesis of different derivatives revealed 
important information about the structure activity-relationship (SAR). The work 
of Jens C. de Groot and Dr. Konrad Büssow (Division of Structural Biology, 
Helmholtz Centre for Infection Research, Braunschweig, Germany) revealed that 
besides a plenty of van der Waals contacts between PPARγ and the ligands phenyl 
and isoprenyl residues a complex network of hydrogen bonds is formed between 
Ser342 and Arg288 and the amorfrutins carboxyl group. We further could show 
that disruption of these hydrogen bond network by esterification of the amorfrutin 
carboxyl group leads to loss of the high binding affinity. The methylester A5ME 
has a binding constant of 23 µM, in contrast to 590 nM for the carboxylate A5, 
thus esterification decreases the binding affinity by a factor of 39. The enthalpic 
contribution of the carboxyl group is                
mol/kcal.mol/kJ)/ln(K)Kmol/(J.)K/Kln(RTG ii 22939129831821 ≈≈⋅⋅−≈−=∆∆ . 
This is in the range of the common energy contribution of strong hydrogen bonds 
(230) as seen in the crystal structure, and thus is verifying the observed data. 
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We also discovered a series of related amorfrutins binding to PPARγ and further 
to PPARα as well as PPARβ/δ (Figure S1 and table S1). These examples 
disclosed that small modifications at the isoprenyl residue may dramatically 
increase the affinity to PPARγ, and generate ligands in the low-nanomolar range. 
This high affinity is extraordinary for nature-based PPARγ ligands, as most of the 
known non-synthetic ligands have affinities in the micromolar range (83, 231). 
Slight modifications of the amorfrutin structure have a high impact on the 
transcriptional activation of target genes (Figures 14 to 15). Mediators of this 
specificity are the transcriptional cofactors. All amorfrutins presented here 
exhibited unique cofactor recruitment profiles (Figure 10 and table S2), probably 
as a result of different PPARγ conformations induced upon ligand binding. 
Therefore it is supposed that, consequently, pharmacologic properties – ADME 
parameters, anti-diabetic efficacy and safety – can directly be fine-tuned by 
derivatisation of the amorfrutin core structure. This principle has already been 
observed with other PPAR ligand classes. For instance, in clinical use 
rosiglitazone does barely improve lipid parameters (e.g. HDL- and LDL-
cholesterol) (232) and increases the risk of congestive heart failure (233), while 
pioglitazone is associated with improvements in lipid parameters (232) and does 
not adversely affect cardiovascular diseases (234).  
Albeit not endogenously present, structural similarity of the amorfrutins to 
potential physiologic ligands is a matter of discussion. The core structure of the 
amorfrutins is partly reminiscent to that of vitamin B6, especially of the pyridoxal 
form, which is required for amino acid catabolism and glycogenolysis (235, 236). 
It already has been reported that vitamin B6 deficiency is linked to impaired 
gluconeogenesis (237) and that administration of pyridoxal or pyridoxamine 
improves diabetes in several animal models (238, 239). Therefore the binding of 
pyridoxal to PPARγ was tested using the TR-FRET assay. However, pyridoxal 
showed no binding to the PPARγ-LBD. This may be attributed to the missing 
phenyl and isoprenyl residues that are needed for numerous van der Waals 
contacts. To systematically search for potential similar endogenous ligands we 
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scanned the Human Metabolom Database (HMDB) (240). The Tanimoto 
similarity search (threshold 0.6) revealed likeness to several intermediates of the 
ubiquinone biosynthesis, e.g. to 3-Hexaprenyl-4-hydroxy-5-methoxybenzoic acid 
and 3-Hexaprenyl-4,5-Dihydroxybenzoic acid. Ubiquinone is required as mobile 
electron transporter between complexes in the electron transport chain. Since it 
has an important role in the oxidative phosphorylation, it could be speculated that 
upon nutrient intake a balanced coregulation of ATP generation and glucose- and 
lipid metabolism would be beneficial. However, neither it was directly shown that 
intermediates of the ubiquinone biosynthesis bind to PPARγ nor it is likely that 
the intermediates located in the mitochondria and the nuclear receptor PPARγ 
have direct contact.   
Since the Tanimoto coefficients only take into account exact congruence between 
query and library structures, I additionally applied the CATS (Chemically 
Advanced Template Search) software developed by Gisbert Schneider (241, 242). 
CATS compares topological pharmacophore descriptors (hydrogen-bond 
donor/acceptor, positively or negatively charged, lipophilic) of two molecules in 
Euclidean space, and thus allows for ‘scaffold hopping’. Noteworthy, the best hits 
belong to the groups of free fatty acids, prostaglandines and thromboxanes, which 
have already shown to contain important physiologic PPAR activators (243, 244). 
Consequently, although amorfrutins are no endogenous ligands in mammals, they 
may mimic physiologic PPAR modulators in terms of metabolic regulation. 
The structure of the widely applied glitazones was derived from the fibrate class 
(73), and other PPARγ ligands (e.g.ragaglitazar) in turn are adopted from the 
glitazone core structure (245). Amorfrutins are neither similar to 
thiazolidinediones nor to glitazars, both having been associated with tremendous 
side effects. In addition, the amorfrutin lead molecule is much less in molecular 
size, providing the opportunity for further derivatisation and optimisation by 
keeping the molecular weight in an advantageous range. According to Christopher 
A. Lipinski’s rules, oral bioavailability as a property of druglikeness of a 
compound is favoured with less than 5 hydrogen bond donors and 10 hydrogen 
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bond acceptors, a molecular weight not greater than 500, and with a maximal 
calculated partition coefficient (ClogP) of 5 (246). This ‘rule of 5’ is fulfilled by 
all amorfrutins presented here, indicating a particular high druglikeness.  
As recent reports disclosed an important role for PPARγ expressed also in the 
brain (see below) blood-brain-barrier penetration has to be considered. This 
pharmacological property could shown to be correlated with the polar surface area 
(PSA) of the small molecule, which can be approximately calculated (247). 
Amorfrutin 1 has a PSA of ~ 67 Ǻ² (rosiglitazone ~ 72 Ǻ²). It is an accepted 
assumption that drugs that act on the central nervous system must have a PSA 
below 70-80 Ǻ² (248). This indicates that amorfrutins can penetrate the blood-
brain-barrier. This is also supported by high membrane permeability 
experimentally determined in the PAMPA and Caco-2 model.  
The amorfrutins have outstanding structural properties for natural products. In 
general, synthetic, combinatorial chemistry differs strongly from biosynthetic 
processes. Nature uses a relatively small set of building blocks and introduces 
diversity by sophisticated pathways and many functional groups, especially 
numerous different oxidation levels. In addition, natural compounds are products 
of enantioselective reactions. As a consequence, natural products typically have 
about 6 chiral centers, 4 rings, 6 oxygen atoms and 7 and 3 hydrogen bond 
acceptors and donors, respectively. In contrast, chemical synthesis pursues the 
strategy to repeat a moderate number of stereononselective reactions on a lot of 
building blocks. Consequently, synthetic compounds of the same molecular 
weight in average have no chiral centers, only 3 rings, 3 oxygen atoms and 4 and 
one hydrogen bond acceptors and donor, respectively. Comparing compounds 
from combinatorial libraries versus that from natural product collections and drug 
databases revealed the exceptional position of the amorfrutins. They have no 
stereocenter, only one to two aromatic rings, and in general only 5 carbon-oxygen 
bonds. To assess the chemical properties in a more systematic approach, we 
compared 10 compound properties, which are typical for that chemical class 
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(249), using a distance matrix (Figure S9). The amorfrutins are more similar to 
synthesized compounds and drugs than to complex natural products.  
This indicates that chemically synthesizing amorfrutins may be a promising tool 
compared to extensive extraction from Glycyrrhiza spec. As there was no 
amorfrutin synthesis reported so far, our group together with Aman Prasad and 
Prof. Dr. Frank C. Schroeder (Boyce Thompson Institute and Department of 
Chemistry and Chemical Biology, Cornell University, Ithaca, NY, USA) 
developed a 6-stepped synthesis route for amorfrutins with more than 99% purity. 
The synthesis of pure amorfrutins in multigram quantities was a basic requirement 
for several subsequent applications: 1) it provided the crystallisation and structure 
determination of bound PPARγ due to high purity, 2) it allowed for first animal 
studies to verify the anti-diabetic effects in vivo, 3) it facilitates future in vivo 
studies in human patients, and 4) it permits the development of diverse amorfrutin 
analogues by chemical modification. 
In conclusion, the amorfrutin class has a promising potential as lead for the 
chemical generation of optimised PPARγ ligands or even dual and pan PPAR 
agonists. 
 
4.2  The in vitro properties of amorfrutins 
Initial in vitro experiments showed that amorfrutins are potent PPARγ ligands 
with affinity constants in the nanomolar range (table S1). Such competitive 
binding studies are well established tools to quantify small molecule binding 
affinities, although the data of this artificial set-up could be completed by 
additional assays like isothermal binding calorimetry (ITC) and nuclear magnetic 
resonance (NMR) chemical shift perturbation approaches without the need of 
fluorescence labelling. 
Additional cofactor binding experiments revealed recruitment profiles that were 
strikingly distinct from those of the thiazolidinedione class. Binding of different 
(but structural similar) ligands induced very specific cofactor recruitment 
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signatures. However, effective (amorfrutin) concentrations of cofactor recruitment 
varied between different amorfrutins and cofactor peptides. For instance, 
amorfrutin 1 (Ki = 236 nM) and amorfrutin 3 (Ki = 352 nM) recruited CBP-1 with 
EC50 of 12 µM and 110 nM, respectively, and they led to release of NCOR-2 
with IC50 of 51 nM and 2.8 µM, respectively (table S2). The observed EC50 
values are partly not in agreement with the compound binding affinities. 
Obviously, already under cell-free conditions with simplified peptides the 
biophysical processes of PPARγ activation are very sophisticated. The peptides 
are derived from the exposed cofactor interaction domain, which in general 
contains a conserved leucine-rich LXXLL motif that directly binds to the PPARγ-
LBD in dependence of the receptor conformation (71). Thus, the EC50 value is 
not only defined by the compound affinity (Ki), but additionally is influenced by 
the affinity of the cofactor peptide to the different PPARγ conformations (which 
was not measured here). The effective concentration of cofactor recruitment 
consequently is composed of various equilibrium binding constants. Therefore it 
is probable that cofactor binding on the PPARγ apo form facilitates binding of the 
small molecule. 
Certainly, the cofactor recruitment assay used here is limited by its artificial 
design. Since many coactivators contain more than one copy of the LXXLL motif, 
cooperative effects which largely influence cofactor binding to PPARγ cannot be 
assessed in such in vitro assays. Additionally, non-conserved amino acids terminal 
to the LXXLL motif, which are absent in the derived peptides, also account for 
specificity of cofactor binding (250). The performed cofactor recruitment studies 
present a valuable link between binding and transcriptional activation. Albeit 
several current publications about the role of transcriptional cofactors in 
metabolism (251, 252), few is known about their role in PPAR-driven gene 
expression, and further studies are required. 
A possible approach to use such cofactor recruitment profiling without knowledge 
of the underlying transcriptional processes is a solely descriptive assay – with 
different datasets of compounds with beneficial effects (e.g. SPPARMs) and 
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compounds with adverse effects (e.g. glitazones) it should be possible to screen 
for novel SPPARMs in addition to simple receptor binding assays. This 
methodological concept was recently described in several publications (253-256). 
As inferred from the mouse studies, recruitment of the newly-discovered PPAR 
coactivator TBL1 should also be included to assess the compounds ability to 
enhance fatty acid oxidation. 
In subsequent experiments, the amorfrutins were verified as transcriptional 
PPARγ activators with effective concentrations (458 nM to 4.5 µM) (table 1) that 
partly were above the binding affinities (Ki) up to ten-fold. A reason for the 
discrepancy could include a compound-specific retention outside of the cells, but 
the lipophilicity of the amorfrutins should facilitate diffusion over the cellular 
membrane. Contrary to the in vitro binding assay, transcriptional activation by the 
PPARγ construct only took place in dependence of numerous cellular cofactors. 
Thus, different effective concentrations for the amorfrutins were probably a result 
of different cofactor associations in the cells. That is also a common reason, why 
EC50 values (and efficacy) often are not reproducible in different cell types: 
changing the cellular environment is always accompanied by a different 
expression profile of the transcriptional cofactors.  
Certainly, the reporter gene assay is a very artificial approach to measure nuclear 
receptor transactivation. It is especially limited by the usage of the nonphysiologic 
HEK293 cancer cell line, by overexpression of the chimeric GAL4/LBD construct 
and, in addition, by the reporter gene promoter design containing several copies of 
the upstream activator sequence (UAS). This limitation can be resolved by use of 
PPARγ full length assays with reporter genes under control of a natural PPAR 
response element carried out in common target cells such as adipocytes or 
macrophages. 
The differential recruitment of cofactors to PPAR target genes is the key for 
understanding of transcriptional effects modulated by ligands. However, all 
reporter gene assays and in vitro recruitment studies disregard the importance of 
the complex gene promoter architecture, as different target genes expressed in the 
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same cell type can be variably associated with different cofactors (257-259). A 
more comprehensive view of compound-specific cofactor recruitment and gene 
expression will be gained by systematic whole-genome approaches such as 
chromatin immunoprecipitation coupled to next generation sequencing (ChIP-seq) 
(260). With a deeper knowledge about the association of certain cofactors and 
target genes responsible for beneficial and adverse effects in clinical usage 
directed screening assays will allow to separate the wheat from the chaff of 
nuclear receptor ligands.  
 
4.3  Cell culture studies with amorfrutins 
As shown in murine and human adipocytes, the amorfrutins modulate 
transcription of PPARγ target genes. To verify the specificity amorfrutins siRNA-
mediated PPARγ knockdown studies were performed in primary adipocytes. 
Although PPARγ knockdown resulted in complete inhibition of amorfrutin effects 
at two of four genes, residual transcriptional activation persisted at two genes. It 
cannot be excluded that the remaining PPARγ expression of ca. 20% is sufficient 
to influence expression of target genes. Application of additional siRNA 
molecules with different sequences could further boost PPARγ knockdown. 
Efficiency should also be assessed on protein scale. Probably, transcriptional 
activation of the two persisting genes was modulated by PPARα and PPARβ/δ, 
since amorfrutin 1 and 2 also slightly activate these isotypes (table 1). The 
investigated common target genes are not specific for PPARγ and all three PPAR 
subtypes are expressed in adipocytes. Further validation may include 
simultaneous knockdown of PPARα and β/δ as well and use of a more specific 
PPARγ ligand, e.g. amorfrutin 3. Molecular targets of amorfrutins in cells could 
also be investigated with capture compound mass spectrometry (261). Coupling of 
a reactive biotinylated linker to amorfrutin, e.g. via the 4-hydroxy-residue that is 
presumably not involved in PPARγ binding, and subsequent analysis of captured 
cellular proteins would elucidate potential targets in the whole proteome. 
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To investigate the regulative effects on expression of the whole genome primary 
human adipocytes were treated for 24 hours with amorfrutins. The compound 
concentration was below the maximal concentration tested in the cellular toxicity 
assay, so that toxic effects are unlikely. An amorfrutin concentration of 30 µM 
was applied that was above the effective concentration determined in the reporter 
gene assay to ensure saturation of cellular PPARγ with the compound. Similar 
effects on gene expression have also been observed with only 10 µM of 
amorfrutin 4 (data not shown). Comparison of the different gene expression 
patterns figured out that the SPPARMs regulated fewer genes and that with 
reduced magnitude. The presented heatmap of differentially regulated genes 
(Figure 15) indicates that the different PPARγ ligands have very distinct gene 
expression patterns. However, due to filtering of regulated genes using an 
arbitrary threshold of P < 0.05 it has to be considered, if genes that were 
obviously not regulated are just (slightly) below this cut-off. To address this, a 
Gene Set Enrichment Analysis (GSEA) was performed on the whole-genome data 
(Figures 16, 17 and S4). This approach has the advantage to cumulate expression 
levels of many genes belonging to a certain gene set (e.g. pathway). Hence, also 
slight regulation of several genes becomes detectable and allows a reliable 
comparison of compound profiles. The GSEA approach revealed that important 
PPARγ pathways as lipid and glucose metabolism, but also anti-inflammatory 
processes were regulated with amorfrutins similar to rosiglitazone. Selective 
PPARγ modulation by amorfrutins was substantiated by use of principal 
component analysis and gene distance matrix, which integrated the majority and 
all of the gene expression data, respectively. 
 
4.4  The effects of amorfrutins in mice 
Three different mouse models were chosen to evaluate the in vivo anti-diabetic 
effects of amorfrutins in different stages of type 2 diabetes. The potential of 
prevention of insulin resistance was investigated in common C57BL/6 mice that 
were simultaneously fed for 15 weeks with a high fat diet, thus mimicking an 
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unhealthy Western diet. Amorfrutin 1 significantly inhibited the development of 
obesity, insulin resistance, hypertriglyceridemia, lipid deposit in non-adipose 
tissue and low-grade ‘metaflammation’. The observed reduction in liver steatosis 
with amorfrutin treatment can be explained by activation of the PPARα isotype, 
which is not targeted by rosiglitazone. This observation clearly shows the 
advantage of amorfrutins and of dual PPAR ligands in general, thus predicting the 
success of other amorfrutin variants that activate PPARα to a greater extend. 
Although rosiglitazone was more efficient in reducing glucose intolerance the 
natural product amorfrutin class revealed a promising potential for the preventive 
application of diet-induced insulin resistance and associated disorders. 
Anti-diabetic effects of amorfrutins were further proved in obese and insulin 
resistant C57BL/6 mice that were previously fed with HFD to induce these 
metabolic disorders. This gave the opportunity to analyze the compound effects in 
a therapeutic format that mimics the phenotype of the malnutrition-based early 
stages of type 2 diabetes. Amorfrutin 1 clearly improved insulin sensitivity, 
glucose tolerance and dyslipidemia as well as the standard drug rosiglitazone.  
Strikingly, amorfrutin 1 decreased the body weight by ~10%, whereas 
rosiglitazone had no effect on body weight. Additionally expression of uncoupling 
proteins (Ucp) as markers of thermogenesis in various tissues was determined. 
However, expression of Ucp in vWAT and liver was more increased with 
rosiglitazone than with amorfrutin treatment (data not shown). This indicates that 
induced thermogenesis alone cannot explain the difference in body weight change 
between both PPARγ ligands. Treatment was not associated with decreased food 
intake, instead amorfrutin (and rosiglitazone) surprisingly led to increased food 
intake (Figure 22). The discrepancy between rosiglitazone-induced thermogenesis 
and weight gain was a subject of current publications. Several reports disclosed an 
involvement of central nervous system (CNS) PPARγ in the regulation of energy 
balance (262-265), especially by a cross-talk with the hypothalamic-pituitary-
thyroid (HPT) axis. According to that some studies could shown that CNS 
PPARγ, which becomes activated during HFD-feeding by endogenous ligands or 
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by administered rosiglitazone, stimulates food intake and weight gain. This was 
accompanied by decreased concentrations of thyroid hormones. Conversely, 
blocking CNS PPARγ by antagonists or shRNA decreased feeding and weight 
gain and also elevated thyroid hormones. However, in the HFD-study presented 
here amorfrutin 1 increased food intake as PPARγ agonists (e.g. rosiglitazone), 
but decreased body weight such as PPARγ antagonists. To explain this 
observation, several pharmacologic effects have to be considered. First, affecting 
CNS PPARγ by amorfrutin requires the transport through the blood-brain-barrier, 
which was not addressed here (see below). Second, regulation of appetite and 
weight gain are separated processes (266) that involve action on CNS PPARγ and 
peripheral PPARγ (267). Thus, differential modulation of PPARγ in different 
tissues, a conceptual hallmark of SPPARγMs, may have opposing effects on food 
intake and weight gain. Third, the selectivity of PPAR ligands to the three PPAR 
subtypes influences energy intake and homeostasis (266), as PPARα and β/δ 
agonists seem to reduce body weight and food intake, whereas PPARγ agonists 
favor the reverse effects (224). Pan PPAR agonists, e.g. bezafibrate, have been 
reported to induce weight loss with or without increased food intake (268-270). 
Amorfrutin 1, which is able to activate all three PPAR subtypes in vitro (Figure 8 
and table 1), apparently behaves as a pan agonist in vivo.  
To address the cross-talk with the HPT axis, the plasma concentrations of thyroid 
hormones such as triiodothyronine (T3), tetraiodothyronine (T4) and thyroid-
stimulating hormone (TSH) should be measured. Besides, isolation of 
hypothalamic tissue and analyzing expression levels of genes for thyroid hormone 
receptor and thyrotropin-releasing hormone could be performed. In addition, 
plasma concentrations of ketone bodies could be determined to explore catabolic 
effects. Furthermore, it has to be considered that appetite and energy homeostasis 
is also regulated by the endocannabinoid system (271), which is linked to leptin 
signalling (272) and can be modulated by PPAR ligands as well (273). The 
control of appetite and energy balance underlies a very sophisticated network of 
neuroendocrine processes, which cannot be easily addressed with few control 
experiments.  
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Of note, an increase in food intake became present not until day 10 of treatment 
with amorfrutin and rosiglitazone, whereas weight loss already started during the 
first days (Figure 22). It can therefore be speculated that orexigenic effects are 
secondary to anti-diabetic and antiobesity actions. Although not determined in this 
experiment, reduced leptin hormone concentration as characteristic of PPARγ 
activation probably led to increased appetite in the course of this treatment. 
Further animal studies of different PPAR-activating classes, e.g. with the more 
PPARγ specific ligand amorfrutin 3, and deciphering the complex regulative 
network of whole-body energy balance will gain deeper comprehension. 
In addition to these two mouse models, leptin receptor-deficient db/db mice were 
treated with amorfrutin 1 in order to determine its anti-diabetic potential in a 
model of severe type 2 diabetes. Whereas rosiglitazone induced weight gain, 
amorfrutin 1 did not affect body weight or food intake, indicating that leptin has 
an important role in mediating orexigenic and anorexigenic effects of amorfrutins. 
However, treatment of diabetic mice clearly ameliorated insulin sensitivity and 
reduced pancreatic tissue exhaustion and dyslipidemia.  
Recent studies showed that HFD-induced phosphorylation at serine 273 of PPARγ 
leads to dysregulation of a large number of obesity-related genes and is coupled to 
insulin resistance (147). Therefore, inhibition of Ser273-phosphorylation was 
proposed as a new strategy to specifically increase insulin sensitivity without 
activating the full range of PPARγ targets associated with side effects (149). This 
novel concept explains the good anti-diabetic properties of SPPARγMs, which 
only partially activate PPARγ. Indeed, amorfrutins block the phosphorylation and 
the subsequent dysregulation of diabetes-related genes (Figures 27 to 28). 
Although the new role of Ser273 PPARγ phosphorylation needs to be further 
studied, this work emphasizes the mechanistic overlap between compounds with 
similar anti-diabetic efficacy but completely different PPARγ activation. 
Amorfrutins thus may be promising members of next generation PPARγ ligands 
that separate anti-diabetic actions from common side effects.  
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To summarize the three animal studies, the amorfrutin class revealed prominent 
effects on the prevention and therapy of insulin resistance and associated 
disorders. Short-term treatment with high dose as well as long-term treatment with 
low dose revealed anti-diabetic effects in three mouse models similar to the 
standard drug rosiglitazone. Additionally, the amorfrutins showed promising 
improvement of dyslipidemia and abnormal lipid deposit superior to rosiglitazone. 
It further disclosed outstanding reduction in HFD-induced obesity and confirmed 
safety regarding liver toxicity. Amorfrutin 1 as well as rosiglitazone revealed 
similar anti-inflammatory and anti-diabetic properties in the mouse studies. It is 
speculative, if the improvements in insulin sensitivity are a result of anti-
inflammatory effects, or if the reverse is true. Both processes are inevitably linked 
to each other and cannot be easily separated (8). To unravel the chain of cause and 
effect a more time-resolved study design would be required. For instance, the 
chronological occurrence of anti-inflammatory vs. anti-diabetic effects could be 
determined. Taken together, the presented mouse studies clearly showed that 
amorfrutins strongly improve insulin resistance as well as several other important 
metabolic and inflammatory parameters. 
 
4.5  Future perspectives 
4.5.1  Further studies 
The ADMET studies elucidated well aqueous solubility and intestinal membrane 
permeability but only minor stability for amorfrutins during liver metabolic 
processes. Furthermore, oral application of amorfrutin 1 in mice led to 
glucuronidation of its carboxyl group and, to a minor extend, to oxidation of the 
isoprenyl residue. It should be a relevant purpose to optimize the ADMET 
properties of the amorfrutins. Based on the presented in vitro studies and X-ray 
structure of bound amorfrutin, it can be assumed that glucuronidation of the 
carboxyl group diminishes the pharmacological effects of PPARγ modulation. For 
a comprehensive view on the impact of that modification additional 
pharmacokinetic studies are required. It is speculative, if chemical protection of 
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the carboxyl function, e.g. by hydrolysable ester groups, will increase the cellular 
concentration of the carboxylated form.  
In contrast, oxidation at the isoprenyl residue is believed to have no major effects 
on PPARγ affinity, since first, the high-affine amorfrutin 3 also has a similar 
residue in its parent form, and second, the X-ray structure does not indicate a 
major contribution of distinct single atoms within the exchangeable isoprenyl 
group. On the other side, this is apparently not true for the binding to PPARα or 
β/δ (Figure 8 and table 1). Furthermore, marginal structural changes within the 
amorfrutins have an important impact on the cofactor recruitment and on the 
selective expression of distinct sets of genes. Consequently, optimizing ADMET 
properties has always to be critically balanced with the pharmacological profile. 
Another aspect of optimizing pharmacological parameters should focus on the 
blood-brain-barrier permeability in order to address neuronal disorders.  
The presented study mainly focuses on the change in gene expression as a key 
marker of compound and diet-induced effects. However, enzymatic and hormonal 
processes are generally regulated by proteins. A major strategy to control the 
levels of proteins is their degradation, so that transcriptional changes are not 
obligatory translated into stable proteome alterations. It would therefore be an 
interesting objective to determine protein expression patterns in the corresponding 
tissues. The application of protein expression arrays is a complementary method 
to investigate compound and diet-induced effects. In addition, the supposed 
pivotal role of PPARγ-Ser273 phosphorylation underscores the importance of 
posttranslational modifications of the proteome. For such sophisticated purposes 
the usage of high resolution liquid chromatography mass spectrometry (LC-MS) 
with previous enrichment approaches seems obvious. For comparative profiling 
approaches such technologies yet requires labelling strategies to enable accurate 
quantification (274, 275). 
To complete the systems biological investigation it would be interesting to 
analyze metabolomic data. Since nutritional alterations, progression of metabolic 
disorders and their pharmacological counteraction impair the homeostasis of 
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metabolites, metabolomics provide a valuable tool to complement gene expression 
profiles.   
The presented work exclusively focuses on anti-diabetic effects of the amorfrutin 
class. In addition, further PPARγ ligands from synthetic libraries were identified. 
This includes a class of chalcones that bound to PPARγ with nanomolar binding 
constants. However, chalcone treatment of mice did not prevent the onset of HFD-
induced insulin resistance, likely due to its low bioavailability observed in ADME 
experiments. 
 
4.5.2  Pharmaceutical applications of amorfrutins 
The studies presented here clearly show the high potential of the amorfrutin class 
for effectively preventing and treating type 2 diabetes and the metabolic syndrome 
with minimized side effects. Metabolic diseases evolved to a global epidemic with 
rapidly growing incidence (1). Since current pharmaceutical interventions are 
affected by severe side effects such as weight gain potentially counteracting the 
pharmaceutical purposes, amorfrutins offer an alternative for that use. This work 
introduced firstly that oral application of the amorfrutin class can attenuate the 
development of diabetes and obesity. Secondly, short-term treatment improves 
insulin sensitivity in mice with severe type 2 diabetes as efficiently as 
rosiglitazone. Therefore, amorfrutins could be used as preventive and therapeutic 
compound to combat type 2 diabetes. Amorfrutins and amorfrutin-containing 
plant extracts or fractions could be applied as non-prescriptive phytomedical 
agents by diabetes-prone patients and health-conscious consumers to prevent 
insulin resistance. Further preclinical and clinical studies are needed to validate 
efficacy and safety of amorfrutins. For treatment of patients with type 2 diabetes, 
additional studies should include combination therapies, e.g. with metformin or 
sulfonylurea.  
Amorfrutins inhibit the progression of diet-induced obesity and lead to stable 
weight loss in obese mice within few days. Pharmaceutical strategies to treat 
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obesity are rare. Currently, only orlistat (Xenical) is approved for that indication, 
but it is linked to gastrointestinal side effects. Since obesity is a rapid growing 
epidemic and one leading cause for metabolic disorders, innovative drugs are 
required. Oral application of amorfrutins may be used for the safe prevention and 
treatment of obesity, although long-term studies are needed.  
PPARγ also plays a central role in inflammatory and autoimmune diseases (276, 
277). Of note, several non-steroidal anti-inflammatory drugs (e.g. indomethacin 
and ibuprofen) also possess activity on PPARγ (278), and it was postulated that 
these antiphlogistics partly act via PPARγ (279). Indeed, PPARγ ligands were 
shown to have therapeutic activity e.g. in acute inflammation (280), arthritis (281, 
282), atherosclerosis (111, 283) and inflammatory bowel diseases (284, 285). Of 
note, amorfrutins were shown to inhibit LPS-induced inflammation in mice by an 
unknown mechanism (286). Thus, it is obvious to investigate the anti-
inflammatory potential of amorfrutins in further animal models and clinical 
studies.  
Its important role in inflammation and lipid metabolism let PPARγ become a 
promising target in skin diseases. For instance, in psoriasis and atopic dermatitis, 
which are characterized by impaired lipid barrier formation, systemic or local 
application of PPARγ ligands improved the severity of skin disorders (287, 288). 
Currently, for these applications the drug of first choice are glucocorticoids that 
are associated with side effects such as skin atrophy (289). This is especially a 
problem in younger patients, which are predominantly affected (290). Treatment 
of skin diseases with amorfrutins in order to facilitate the therapy with less or 
without glucocorticoids may become a new efficient approach. 
Other application fields of PPARγ modulators include neurodegenerative 
diseases. PPARγ ligands exert neuroprotective activity in Parkinson’s disease, 
Alzheimer’s disease and multiple sclerosis beside others (291). As a prerequisite 
for drugs acting on the central nervous systems, blood-brain-barrier penetration 
has to be assured. 
Discussion - 103  
The development of a synthesis route was an important prerequisite for large-
scale application, albeit the yield needs to be optimized. The chemical synthesis 
nevertheless allows for further modification of the amorfrutin lead, thus their core 
structure can serve as template for the development of analogues. Alternatively to 
synthesized agents, purified natural amorfrutins or special extract preparations can 
be used. 
Despite their potential application forms, major challenges remain to bring 
amorfrutins to pharmaceutical use. Since several former PPAR ligands were 
associated with severe side effects, the question of long-term safety has to be 
addressed accurately. Thus, the regulatory agencies claim complete 2-year 
carcinogenicity studies in rodents before beginning clinical trials of at least 6 
months duration (142). Furthermore, in the field of diabetes and dyslipidemia 
several established therapies, e.g. metformin, sulfunylureas, fibrates and statins, 
already exist. The amorfrutins therefore have not only been proven to be safe in 
single and combinatorial treatments, but additionally must possess superior 
efficiencies as established drugs to become approved. Consequently, application 
strategies have to include the other aforementioned disorders.  
 
4.5.3  Nutraceutical applications of amorfrutins 
The amorfrutins are a class of eatable natural products present in different 
legumes. In addition to an application as drug it therefore is conceivable to 
develop amorfrutin-based nutraceuticals, e.g. as dietary supplement in yoghurt or 
juices. Nutrition not only entails a risk factor for metabolic stress, but also can be 
the key to health. The class of amorfrutins has the potential to be used as 
nutraceutical to prevent the widespread emergence of insulin resistance. 
Generally, dietary modifications are applicable for the prevention of metabolic 
disorders, whereas pharmaceuticals are approved for the treatment of diseases 
(292). Furthermore, amorfrutin-based nutraceuticals could supportingly be used as 
medical food for treatment of present metabolic disorders, as this work clearly 
revealed that amorfrutins have preventive and therapeutic effects on health.  
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However, usage of pure natural products or fractions containing the amorfrutins 
requires high amounts of biomaterial. Alternatively, biotechnical approaches such 
as plant cell fermentation (293) with optimised yield have to be considered. As 
this work unambiguously has shown that a whole amorfrutin class has beneficial 
effects, synergistic actions of crude extracts with different amorfrutins may be 
applicable. The class of simple 2-hydroxybencoic acid derivatives is not restricted 
to Glycyrrhiza spec. and Amorpha spec., since related compounds with PPARγ-
modulating activity are also produced in other plants and fungi (table S1). The 
exploitation of other herbal or microbial sources thus seems reasonable.  
In summary, besides its high potential for pharmaceutical applications amorfrutins 
constitute a promising natural-product class for the development of nutraceuticals 
to prevent metabolic diseases.  
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5  Summary 
Considering the rising pandemic expansion of metabolic disorders there is an 
urgent need for new concepts addressing prevention and treatment of diseases 
such as type 2 diabetes and obesity. Diabetes and its complications are considered 
the major cause of death in many countries and entail a huge impact on public 
health systems. Having a key role in lipid and glucose homeostasis, the nuclear 
receptor PPARγ (peroxisome proliferator-activated receptor gamma) presents an 
important target for anti-diabetic compounds. However, treatment with currently 
approved PPARγ-modulating drugs is associated with severe side effects such as 
weight gain and necessitates the development of next-generation PPARγ ligands. 
The present work introduces a new class of potent PPARγ ligands. The 
‘amorfrutins’ present a family of natural products isolated from the eatable 
legumes Amorpha fruticosa and Glychyrrhiza foetida (liquorice). The amorfrutins 
strongly bind to PPARγ and selectively modulate expression of PPARγ target 
genes. The expression signatures of amorfrutins are distinctly different compared 
to currently approved PPARγ agonists. In different diabetic mouse models, oral 
treatment with amorfrutins strikingly improved insulin sensitivity, 
hypertriglyceridemia and metabolic inflammation with similar efficacy to current 
anti-diabetic agents. In striking contrast to other PPARγ drugs the amorfrutins 
efficiently uncoupled insulin sensitization from undesired side effects and further 
reduced obesity and tissue lipid accumulation. This work clearly reveals the 
exceedingly high potential of amorfrutins for very effective prevention and 
therapy of type 2 diabetes and associated metabolic disorders with minimized side 
effects. The amorfrutins represent a novel class of selective PPARγ modulators 
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6  Zusammenfassung  
Die rapide steigende, globale Inzidenz von Adipositas und Typ 2-Diabetes erfordert 
dringend neue Strategien zur Prävention und Therapie von metabolischen 
Erkrankungen. Diabetes und seine Folgeerkrankungen sind für einen Großteil der 
Todesfälle verantwortlich und stellen eine globale Herausforderung für die 
öffentlichen Gesundheitssysteme dar. Der nukleare Hormonrezeptor PPARγ 
(Peroxisom-Proliferator-aktivierter Rezeptor gamma) besitzt eine Schlüsselposition 
bei der Lipid- und Kohlenhydrat-Homöostase und ist ein wichtiges 
pharmakologisches Ziel antidiabetischer Wirkstoffe. Der Einsatz derzeit 
zugelassener PPARγ-Aktivatoren ist jedoch mit schwerwiegenden Nebenwirkungen 
verbunden, sodass ein Bedarf an neuartigen, verbesserten PPARγ-Modulatoren 
besteht. Während der hier beschriebenen Promotion gelang es, eine neue Klasse an 
affinen PPARγ-Liganden zu identifizieren und eingehend zu untersuchen. Bei 
diesen sogenannten „Amorfrutinen“ handelt es sich um eine Stoffklasse von 
bioaktiven Naturstoffen, die aus Süßholzwurzeln (Glychyrrhiza foetida) und den 
essbaren Früchten des Scheinindigos (Amorpha fruticosa) isoliert wurden. Die 
Amorfrutine zeichnen sich durch eine hohe Bindungsaffinität zu PPARγ aus und 
modulieren dessen transkriptionelle Aktivität ausgesprochen selektiv. Infolgedessen 
führt die Behandlung mit Amorfrutinen zu Genexpressionsprofilen, die sich 
deutlich von denen derzeit zugelassener PPARγ-Aktivatoren unterscheiden. In 
verschiedenen diabetischen Maus-Modellen bewirkte die orale Applikation von 
Amorfrutinen eine starke Verbesserung der Insulin-Sensitivität, der 
Hypertriglyzeridämie sowie der metabolischen Inflammation. Die antidiabetischen 
Wirkungen waren vergleichbar mit denen klinisch verwendeter Medikamente. Im 
Gegensatz zu letzteren führte die Behandlung mit Amorfrutinen nicht zu den 
bekannten Nebenwirkungen, sondern verringerte darüber hinaus Adipositas und 
Fetteinlagerungen in Organen. Die vorliegende Arbeit zeigt das große Potential der 
nebenwirkungsarmen Amorfrutine, Typ 2-Diabetes und damit verbundene 
metabolische Erkrankungen zu verhindern und zu therapieren. Die Amorfrutine 
stellen einen vielversprechenden Ansatz für die Entwicklung pharmazeutischer 
Wirkstoffe und Nahrungsergänzungsmittel dar. 
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8  Abbreviations 
Abbreviation/Symbol Full name/Meaning 
11β-HSD1 (HSD11B1) Hydroxysteroid (11-β) dehydrogenase 1 
A1 Amorfrutin 1 
ACOX1 Acyl-Coenzyme A oxidase 1 
ACS Acyl- Coenzyme A synthetase 
Adipoq Adiponectin 
ADMET Absorption, Distribution, Metabolism, Excretion, Toxicity 
AF Activation function  
ALT Alanine transaminase 
ANOVA Analysis of variance 
AP-1 Activating protein-1 
Arg Arginine 
ATF6 Activating transcription factor-6 
ATP Adenosine triphosphate 
AUC Area under the curve 
AUCi Inverse area under the curve 
BMI Body mass index 
BSA Bovine serum albumin 
CATS Chemically Advanced Template Search 
CBP CREB-binding protein 
CREB cAMP response element-binding protein 
cDNA Complementary DNA 
CNS Central nervous system 
CPT Carnitine palmitoyltransferase 
cRNA Complementary RNA 
CRP C-reactive protein 
DAG Diacylglycerol 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DBD DNA-binding domain 
Abbreviations - 126  
DIO Diet-induced obesity 
DMEM Dulbecco's modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DPP-4 Dipeptidyl peptidase-4 
EC50 Effective concentration (at 50%) 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycoltetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
FABP Fatty acid binding protein 
FATP Fatty acid transport protein 
FBS Fetal bovine serum 
FDR False discovery rate 
FFA Free fatty acids 
FRET Fluorescence resonance energy transfer 
GDM Gene distance matrix 
GLP-1 Glucagon-like peptide 1 
GLUT4 Glucose transporter 4 
GSEA Gene Set Enrichment Analysis 
GST Glutathione S-transferase 
GyK Glycerol kinase 
HDL High-density lipoprotein 
HFD High-fat diet 
HOMA Homeostatic model assessment 
HPLC High performance liquid chromatography 
HPT axis Hypothalamic-pituitary-thyroid axis 
IBMX 3-isobutyl-1-methylxanthine 
IC50 Inhibitory concentration (at 50%) 
IgG-HRP Immunoglobin G – horseradish peroxidase 
IKK Inhibitor kappa B kinase 
IL-1 Interleukin 1 
Abbreviations - 127  
IL-6 interleukin 6 
IPIST Intraperitoneal insulin sensitivity test 
IR Insulin Resistance 
IRE1 Inositol requiring enzyme 1 
IRS-1 Insulin receptor substrate 1 
JNK JUN N-terminal kinase 
Ki Affinity constant 
LBD Ligand-binding domain 
LDL Low-density lipoprotein 
LFD Low-fat diet 
LPL Lipoprotein lipase 
LPS Lipopolysaccharides 
LXR Liver X receptor 
MCP-1 Monocyte chemotactic protein-1 
MIAME Minimum Information About a Microarray Experiment 
mTOR Mammalian target of rapamycin 
NCOR Nuclear receptor corepressor 2 
NF-κB Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 
NMR Nuclear magnetic resonance 
NR Nuclear receptor 
OGTT Oral glucose tolerance test 
P P value 
PAI-1 Plasminogen activator inhibitor-1 
PAMPA Parallel artificial membrane permeability assay 
PBS Phosphate buffered saline 
PCA Principal component analysis 
PCR Polymerase chain reaction 
PEPCK Phosphoenolpyruvate carboxykinase 
PERK PKR-like eukaryotic initiation factor 2α kinase 
PGC1α PPARγ coactivator 1α 
PI3K Phosphoinositide 3-kinase 
Abbreviations - 128  
PKC Protein kinase C 
PKR Double-stranded RNA-activated protein kinase 
PLTP Phospholipid transfer protein 
PPAR Peroxisome proliferator-activated receptor 
PSA Polar surface area 
qPCR Quantitative PCR 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Ros, R Rosiglitazone 
RXR Retinoid X receptor 
s.d. Standard deviation 
s.e.m. Standard error of mean 
SDS Sodium dodecyl sulfate 
Ser Serine 
shRNA Small hairpin RNA 
siRNA Small interfering RNA 
SPPARM Selective PPAR modulator 
SRC Steroid receptor coactivator 
TBL1 Transducin beta-like 1 
TLR Toll-like receptor 
TNFα Tumor necrosis factor α 
TR-FRET Time-resolved fluorescence resonance energy transfer 
TZD Thiazolidinedione 
UAS Upstream Activation Sequence 
UCP Uncoupling protein 
UPR Unfolded protein response 
Veh Vehicle 
vWAT Visceral white adipose tissue 
WAT White adipose tissue 
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9.1  Supplementary Figures 
 
NP-015142 NP-006431 NP-015136 NP-002329
NP-001620 NP-006243 NP-015935 NP-015936
NP-015934 NP-001728 NP-001727 NP-012411 NP-006427
 
 
Figure S1. Structures of further amorfrutins. 
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Figure S2. Cellular activation of PPARγ by amorfrutins determined in a competitive
reporter gene assay. To accurately determine EC50 and efficacy values, the reporter cells
were additionally treated with the indicated concentrations of amorfrutins in presence of
7 nM rosiglitazone. Data are expressed as mean ± s.d. (n=3). 
A B 
C D 








0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9



















Figure S3. Correlation of gene expression regulation obtained by Illumina Bead Array and
qPCR. Four genes were arbitrary chosen and displayed as follows: ADIPOQ (blue
diamonds), NR1H3 (red circles), HSD11B1 (orange triangles), FABP4 (light blue
squares). Pearson product-moment correlation coefficients are indicated for each gene. 






























































Figure S4. Gene Set Enrichment Analysis (GSEA) of expression profiles using the 
MsigDB C2 gene sets including KEGG pathways and data from chemical and genetic 
perturbation experiments. Normalized enrichment scores are shown for gene sets with 
FDR≤0.25 for at least one compound. Gene sets were either up-regulated (red) or down-
regulated (blue) in the compound expression profiles. 
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Figure S6. Effect of treatment on plasma alanine transaminase (ALT) in DIO mice (n=13, 
3 weeks), db/db mice (n=13, 3 weeks) and C57BL/6 mice (n=12, 15 weeks). Data are 
expressed as mean ± s.e.m. *, P≤0.05 vs. vehicle only. 



























Figure S5. Viability of HepG2 cells treated for 24 h with amorfrutins  was assessed with
the WST-1 reagent. Data are expressed relative to vehicle control and shown as mean ±
s.e.m. (n=3). 
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Figure S7. Effects of low-fat diet (LFD) or high-fat diet (HFD) without or with 
rosiglitazone (HFD+R) or amorfrutin 1 (HFD+A1) on body weight (A) and cumulative 
energy intake (B) in C57BL/6 mice. Data are expressed as mean ± s.e.m.   
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Figure S8. Regulation of gene expression in visceral white adipose tissue (vWAT) after 
feeding of low-fat diet (LFD) or high-fat diet (HFD) without or with rosiglitazone 
(HFD+R) or amorfrutin 1 (HFD+A1) over 15 weeks in C57BL/6 mice (n=12). Expression 
of genes involved in inflammatory processes (A) and presence of macrophage-specific 
markers (B) were analyzed by qPCR. Gene expression of HFD-fed mice is set to 1. Data 
are expressed as mean ± s.e.m. *, P≤0.05 vs. HFD. 
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Figure S9. Distance matrix of ten chemical properties specific for compounds from
combinatorial libraries, drug databases, natural product collections and amorfrutin class.
Squares show the similarity in Euclidean space, ranging from the same properties (black)
to completely different (red). Chemical properties were number of chiral centers, rotatable
bonds, C-N bonds, C-O bonds, C-halogen bonds, C-S bonds, hydrogen bond acceptors and
donors, the ratio of aromatic atoms to ring atoms, and the ring fusion degree in a solvated
environment. Data were taken from ref (249). 
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9.2  Supplementary table
Table S1. Binding affinity constants (Ki) and sources of amorfrutins. Selectivity is the
ratio of the binding constants. 
 
PPARγ PPARα PPARβ/δ PPARα PPARβ/δ
NP-003520 












(Amorfrutin 4) 0.278 8.0 6.0 29 22
Glycyrrhiza foetida, 
Amorpha fruticosa
NP-015142 0.019 2.6 1.8 137 95 Amorpha fruticosa
NP-006431 0.093 7.8 2.3 84 25 Glycyrrhiza foetida
NP-015136 0.134 5.0 1.4 37 10 Amorpha fruticosa
NP-002329 0.264 2.8 2.2 11 8 Anacardium occidentale
NP-016020 0.280 7.0 2.7 25 10 Cannabis sativa
NP-006243 0.305 12 3.8 39 12 fermented fungi   (species undetermined)
NP-015935 0.524 8.2 5.8 16 11 Glycyrrhiza foetida
NP-015936 0.613 4.4 7.0 7 11 Glycyrrhiza foetida
NP-015934 0.508 11 4.5 22 9 Glycyrrhiza foetida
NP-001728 0.860 9.6 n.d. 11 n.d. Picris altissima
NP-001727 1.3 38 38 29 29 Picris altissima
NP-012411 1.6 128 40 80 25 Eriodictyon glutinosum
NP-006427 3.2 n.d. n.d. n.d. n.d. Glycyrrhiza foetida
Biological sourcesCompound Ki [µM] Selectiv ity for PPARγ vs.
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Table S4. Validation of the gene expression signature for rosiglitazone using the
Connectivity Map. Obtained gene lists were compared to other small molecule
experiments in different human cell lines. Eleven of the 13 most significantly correlated
compounds are well-known PPARy ligands including rosiglitazone (4 connections).  
 
 
 rank batch cmap name dose cell score up down instance_id
1 603 rosiglitazone 10 µM PC3 1.000 0.235 -0.175 1233
2 1005 pioglitazone 10 µM PC3 0.997 0.268 -0.140 5930
3 603 15-delta prostaglandin J2 10 µM PC3 0.907 0.212 -0.160 1231
4 1075 pioglitazone 10 µM PC3 0.887 0.259 -0.104 7088
5 1089 pioglitazone 10 µM PC3 0.887 0.222 -0.141 7528
6 60 15-delta prostaglandin J2 10 µM PC3 0.869 0.191 -0.165 446
7 1015 pioglitazone 10 µM PC3 0.853 0.245 -0.104 5977
8 727 rosiglitazone 10 µM PC3 0.829 0.250 -0.089 4457
10 603 troglitazone 10 µM PC3 0.798 0.259 -0.068 1232
11 55 rosiglitazone 10 µM PC3 0.773 0.181 -0.135 430
13 602 rosiglitazone 10 µM HL60 0.741 0.164 -0.139 1174
 
Table S5. Gene Set Enrichment Analysis (GSEA) of liver from DIO mice treated for 23 
days with 4mg/kg/d rosiglitazone, 100 mg/kg/d amorfrutin 1 or vehicle only. Normalized 
enrichment scores (NES) and false discovery rates (FDR q-val) are shown for toxicity 
related pathways adopted from the PAMM-003A RT² Profiler™ PCR Array Mouse Stress 
& Toxicity PathwayFinder (SABiosciences, MD, USA). None of these gene sets was 
enriched within the gene expression profiles. 
 
NES FDR q-val NES FDR q-val
HEATSHOCK 10 1.19 0.517 -0.98 0.609
APOPTOSIS SIGNALING 8 0.56 0.964 -1.44 0.195
DNA DAMAGE AND REPAIR 11 -0.61 0.933 1.03 0.856
PROLIFERATION AND CARCINOGENESIS 6 -0.96 0.637 -1.66 0.100
OXIDATIVE OR METABOLIC STRESS 27 -1.05 0.655 -0.90 0.604
INFLAMMATION 14 -1.08 0.889 0.87 0.631
GROWTH ARREST AND SENESCENCE 6 -1.14 1.000 -1.05 0.681
Rosiglitazone Amorfrutin 1NAME SIZE
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